

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

This website is under construction, and information since 2008 is being updated.

Selected Citations

Mycophenolate Mofetil (CellCept®) Suppresses Acute and Chronic Transplant Rejection

1. Prolongation of Rat Heart Allograft Survival by RS-61443. **Morris RE**, Hoyt G, Eugui E, Allison A: Surgical Forum. 40: 337, 1989.
2. Mycophenolate Acid Morpholinoethyl Ester (RS-61443) is a New Immunosuppressant that Prevents and Halts Heart Allograft Rejection by Selective Inhibition of T and B Cell Purine Synthesis. **Morris RE**, Hoyt G, Murphy M, Eugui E, Allison A: Transplant. Proc. 22: 1659, 1990.
3. Immunosuppressive Effects of the Morpholinoethyl Ester of Mycophenolic acid (RS-61443) on Rat and Non-Human Primate Recipients of Cardiac Allografts. **Morris RE**, Wang J, Blum J, Flavin T, Almquist S, Chu N, Lam Y, Kaloostian M, Allison A, Eugui E: Transplant. Proc. 23 (Suppl 2): 19, 1991.
4. Treatment by Mycophenolate Mofetil of Advanced Graft Vascular Disease in Non-Human Primate Recipients of Orthotopic Aortic Allografts. Klupp J, Dambrin C, Hibi K, Luna J, Suzuki T, Hausen B, Birsan T, van Gelder T, Fitzgerald P, Berry G, **Morris RE**: Amer. J. Transplant. 3: 817, 2004.

Sirolimus (Rapamycin, Rapamune®) Suppresses Acute and Chronic Transplant Rejection

1. A New Pharmacologic Action for an Old Compound. **Morris RE**, Meiser B: Medical Science Research. 17: 609, 1989 (Republished with corrected type setting: Medical Science Research. 17: 877, 1989).
2. Rapamycin: A New and Highly Active Immunosuppressive Macrolide with Efficacy Superior to Cyclosporine. Meiser B, **Morris RE**: Progress in Immunology. 7: 1195, 1989.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

3. A Study of the Contrasting Effects of Cyclosporine, FK506 and Rapamycin on the Suppression of Allograft Rejection. **Morris RE**, Wu J, Shorthouse R: *Transplant. Proc.* 22: 1638, 1990.
4. Effects of Cyclosporin, FK506 and Rapamycin on Graft-Vessel Disease, Meiser BM, Billingham, ME, **Morris RE**: *The Lancet.* 338:1297, 1991.
5. Use of Rapamycin for the Suppression of Alloimmune Reactions in Vivo: Schedule Dependence, Tolerance Induction, Synergy with Cyclosporine and FK506 and Effect on Host-versus-Graft and Graft-versus-Host Reactions. **Morris RE**, Meiser B, Wu J, Shorthouse R, Wang J: *Transplant. Proc.* 23: 851, 1991.
6. Sirolimus (Rapamycin) Halts and Reverses Progression of Allograft Vascular Disease in Non-Human Primates. Ikonen T, Gummert J, Hayse M, Honda Y, Hausen B, Christians U, Berry G, Yock P, **Morris RE**: *Transplantation.* 70: 969, 2000.
7. Sirolimus (Rapamycin) Monotherapy Prevents Graft Vascular Disease in Non-Human Primate Recipients of Orthotopic Aortic Allografts. Dambrin C, Klupp J, Birsan T, Luna J, Suzuki T, Stahr P Hausen B, Christians U, Fitzgerald P, Berry G, **Morris, RE**: *Circulation.* 107 (18): 2369, 2003.

Sirolimus (Rapamycin, Rapamune®) Suppresses of Post Angioplasty Restenosis

1. Effects of Treatment with Cyclosporine, FK506, Rapamycin, Mycophenolic Acid and Deoxyspergualin on Vascular Smooth Muscle Proliferation in Vitro and in Vivo. Gregory C, Pratt R, Huie P, Shorthouse R, Dzau V, Billingham M, **Morris RE**: *Transplant. Proc.* 25: 770, 1993.
2. Rapamycin Inhibits Arterial Intimal Thickening Caused by Both Alloimmune and Mechanical Injury: Effect on Cellular Growth Factor and Cytokine Responses in Injured Vessels. Gregory C, Huie P, Billingham ME, **Morris RE**: *Transplantation (Rapid Communication).* 55: 1409, 1993.
3. Treatment with Rapamycin and Mycophenolic Acid Reduces Arterial Intimal Thickening after Balloon Catheter Injury and Allows Endothelial Replacement. Gregory C, Huang

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

X, Pratt R, Dzau, V, Billingham M, **Morris RE**: Transplantation (Rapid Communication). 59: 655, 1995.

Anit-LFA-1 Monoclonal Antibody Suppresses Acute Transplant Rejection

1. An Anti-Adhesion Molecule (LFA-1, CD11a) monoclonal antibody suppresses ongoing rejection and prolongs heart allograft survival indefinitely without lymphocyte depletion. Nakakura E, Jardieu P, Zheng B, **Morris RE**: J. Heart Lung Transplantation. 11: 223, 1992.
2. Prolongation of Heart Allograft Survival by Anti-LFA-1 Monoclonal Antibody Monotherapy: Mechanisms of Action of Antigen-Specific Unresponsiveness. Nakakura E, Shorthouse R, Zheng B, McCabe S, Jardieu P, **Morris RE**: Transplantation. 62: 547, 1996.
3. Effects of Humanized Monoclonal Antibody to Rhesus CD11a in Rhesus Monkey Cardiac Allograft Recipients. Postern R, Robbins R, Chan B, Simms P, Presta L, Jardieu P, **Morris RE**: Transplantation. 69: 2005, 2000.

CP-690, 550 (Janus Kinase 3 [JAK3] Inhibitor) Suppresses Acute Transplant Rejection

1. Prevention of Organ Allograft Rejection by a Janus Kinase 3 Inhibitor. Changelian P, Flanagan M, Ball D, Kent C, Magnuson K, Martin W, Rizzuli B, Sawyer P, Perry B, Brissette W, McCurdy S, Kudlacz E, Conklyn M, Elliot E, Kosolov E, Fisher M, Strelevitz T, Yoon K, Whipple D, Sun J, Munchhof M, Doty J, Casavant J, Blumenkopf T, Hines M, Brown M, Lillie B, Subramanyam C, Shang-Pao C, Milici A, Beckus G, Moyer JD, Su C, Woodworth T, Gaweco A, Beale, C, Litman, B, Fisher D, Smith J, Zagouras P, Magna H, Saltarelli M, Johnson K, Nelms K, Des Etages S, Haynes L, Kawabala T, Finco-Kent D, Barker D, Larson M, Si M-S, Paniagua R, Higgins J, Holm B, Reitz B, Zhou Y-J, **Morris RE**, O'Shea J, Borie D: Science. 302: 875, 2003.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

2. JAK3 Inhibition as a New Concept for Immune Suppression. Borie D, Ming-Sing S, **Morris RE**, Reitz B, Changelian P: Current Opinion in Investigational New Drugs. 4 (11): 1297, 2003.
3. Immunosuppression by the JAK3 Kinase Inhibitor CP-690, 550 Delays Rejection and Significantly Prolongs Kidney Allograft Survival in Nonhuman Primates. Borie D, Changelian P, Larson M, Si, M-S, Paniagua R, Higgins J, Holm B, Campbell A, Lau M, Zhang S, Flores M, Rousvoal G, Ball D, Hawkins J, Kudlascz E, Brissette W, Elliott E, Reitz B, **Morris, RE**: Transplantation. 79: 791, 2005.

AEB071 (Protein Kinase C Inhibitor) Suppresses T-Cell Responses in Vitro and Suppresses Acute Transplant Rejection

1. The First-In-Class Oral Protein Kinase C (PKC) Inhibitor, NVP-AEB071, Prolongs Renal Allograft Survival in Non-Human Primates (NHP) and Suppresses Lymphocyte Proliferation at Safe Exposures in Human Proof-of-Concept Studies. Wagner J, Evenou J-P, Zenke G, Brinkmann V, Pally C, Bigaud M, Burkhart C, Cottens S, Jung T, Rordorf C, **Morris, RE**: American J. Transplant. 6, Suppl 2: 86, Abstract 57, 2006.
2. NVP-AEB071 (AEB), A Novel Oral Inhibitor of Early T-Cell Activation, Prolongs the Survival of Non-Human Primate (NHP) Kidney Allografts When Used As Monotherapy or At Non-Effective Doses Combined With a Non-Effective Dose of Cyclosporine (CsA). Bigaud M, Wieczorek G, Reisen S, Menninger K, Barbet I, Jean, C, Beerli, C, Audet M, Blancher A, Heusser C, Wagner J, **Morris, RE**: American J. Transplant. 6, Suppl 2: 250, Abstract 546, 2006.
3. NVP-AEB071 (AEB), The Novel Oral Inhibitor of Early T-Cell Activation, Prolongs the Survival of Non-Human Primates (NHP) Kidney Allografts Survival When Combined with Everolimus (RAD), ERL080 (ERL) or FTY720 (FTY) Without Calcineurin Inhibitor. Bigaud M, Wieczorek G, Preussing E, Reisen S, Cordoba F, Audet M, Blancher A, Heusser C, Bruns C, Wagner J, **Morris, RE** : American J. Transplant. 6, Suppl 2: 251, Abstract 550, 2006.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

3. NVP-AEB071 (AEB), A Novel Oral Inhibitor of Early T-Cell Activation, Prolongs Rat Cardiac Allograft Survival When Used Alone and In Combination With Cyclosporine, Everolimus, or FTY720. Bruns C, Pally C, Beerli C, Wieczorek G, Wagner J, **Morris RE**: American J. Transplant. 6, Suppl 2: 316, Abstract 741, 2006.
4. Pharmacodynamics (PD) of T-Cell Inhibition by the New Protein Kinase C (PKC) Inhibitor, NVP-AEB071 (AEB) in Non-Human Primates (NHP). Bigaud M, Burkhart C, Raulf F, Vedrine C, Maurer C, Allard C, Preussing E, Cordoba F, Heusser C, **Morris RE** : American J. Transplant. 6, Suppl 2: 697, Abstract 1896, 2006.
5. First Escalating Single Dose Human Volunteer Study of the Novel Immunosuppressant (IS) NVP-AEB071 (AEB): Relationships among Dose Levels, PK and PD of Immune Functions. Burkhart C, Welzenbach K, Raulf F, Vitaliti A, Grenet O, Schmidli H, Belleli R, Marbach P, Wagner J, **Morris RE**, Rordorf C: American J. Transplant. 6, Suppl 2: 698, Abstract 1897, 2006.
6. Pharmacokinetics (PK) of the Novel Oral Protein Kinase C (PKC) Inhibitor NVP-AEB071 (AEB) in Rats and Non-Human Primates (NHP): Study of Immunosuppressive (IS) Efficacy and Distribution to Lymphatic Organs. Weckbecker G, Jean C, Pally C, Wagner J, **Morris RE**, Bruns C: American J. Transplant. 6, Suppl 2: 768, Abstract 2114, 2006.
7. Enzymatic & Cellular Characterization of NVP-AEB071 (AEB), A Novel & Selective Protein Kinase C (PKC) Inhibitor That Blocks Early T-Cell Activation, and Its Use to Define the Role of PKC in T Cells. Evenou J-P, Brinkmann V, Towbin H, Welzenbach K, Cottens S, Wagner J, **Morris R**, Zenke G: American J. Transplant. 6, Suppl 2: 1026, Abstract 2954, 2006.
8. Pharmacological Inhibition of Protein Kinase C Prevents Early T-Cell Activation and Suppresses Organ Allograft Rejection. Wagner J, Zenke G, Baier G, Bigaud M, Evenou J-P, Brinkmann V, Pally C, Wieczorek G, Weckbecker G, Beerli C, Bruns C, Heusser C, Burkhart C, Welzenbach K, Kovarik J, Gruber T, Lutz-Nicoladoni C, Thuille N, Albert R, Cooke N, Sedrani R, van Eis M, Vangrevelinghe E, von Matt P,

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

Marbach P, Dumortier T, Geiser M, Strauss A, Rummel G, Stark W, **Morris RE**,
Cottens S: Submitted, 2008.

Reviews

1. Rapamycins: Antifungal, Antitumor, Antiproliferative and Immunosuppressive Macrolides.
Morris RE: Transplant. Review. 6: 39, 1992.
2. New Immunosuppressive Drugs. **Morris RE**: In "Transplantation of the Liver" R Busuttill,
G Klintmalm (Eds). WB Saunders. Pp 760-786, 1996.
3. Molecular Mechanisms of Action of New Xenobiotic Immunosuppressive Drugs:
Tacrolimus (FK506), Sirolimus (Rapamycin), Mycophenolate Mofetil and Leflunomide.
Brazelton T, **Morris RE**: Current Opinion in Immunol. 8: 710, 1996.
4. Leflunomide and Malononitrilamides. Silva H, **Morris RE**: Expert Opinion in Investigational
Drugs. 6: 51, 1997.
5. Unapproved Nonbiologic Immunosuppressants. Klupp J, **Morris RE**: In "Primer on
Transplantation." D Norman, L Turka (Eds). American Soc. of Transplantation. Pp
165-172, 2001.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

PATENTS

1. **Morris, R.E.**; Concanavalin A Dimers as Therapeutic Agents," U.S. Patent #4,889,842, issued 12/26/89.
2. Gregory, C, **Morris, R.E.**: "Methods of Treating Hyperproliferative Vascular Disease," U.S. Patent 5,283,257, issued 2/94.
3. **Morris, R.E**, Gregory, C.: "Method of Treating Hyperproliferative Vascular Disease," U.S. Patent 5,563,146, issued 10/8/96 (continuation).
4. **Morris, R.E**, Drell, W., Fox R.: "Administration of Azaribine to Control Ongoing Rejection", issued 1996.
5. **Morris, R.E.**, Drell, W., Fox R.: "Method for Inhibiting Allograft Rejection by the Administration of 6-Azauridine or its Triacetate Derivative," issued 1996.
6. **Morris, R.E**, Bartlett, R.: "Method of Treating Hyperproliferative Vascular Disease," United States Patent #5,519,042, issued 5/21/96.
7. **Morris, R.E**, Gregory, C.: "Method of Treating Hyperproliferative Vascular Disease with Rapamycin and Mycophenolic Acid," U.S. Patent #5,646,160, issued 7/8/97.
8. **Morris, R.E**, Gregory, Clare R.: "Method of Treating Hyperproliferative Vascular Disease" United States Patent #5,665,728, issued 5/9/97.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

JOURNAL ARTICLES

1. **Morris RE** and Lucas ZJ.: Immunologic enhancement of rat kidney grafts: Evidence for peripheral action of homologous antiserum. *Transplant. Proc.*, 3:697-700, 1971.
2. **Morris RE**, Enomoto K, Kay GL, Dong E, and Shumway NE: Prolongation of rat renal allograft survival by chicken anti-rat lymphocyte globulin. *Transplant. Proc.*, 5:535-540, 1973.
3. Caves PK, Dong E Jr., **Morris RE**, and Shumway NE: The immunologic diagnosis of orthotopic cardiac allograft rejection in dogs. *Transplant. Proc.*, 5:745-748, 1973.
4. Caves PK, Dong E Jr., **Morris RE**, and Shumway NE.: Hyper-acute rejection of orthotopic cardiac allografts in dogs following solubilized antigen pretreatment. *Transplantation*, 16:252-256, 1973.
5. Souther SG, **Morris RE**, and Vistnes LM: Prolongation of rat cardiac allograft survival by splenectomy following transplantation. *Transplantation*, 17:317-319, 1974.
6. **Morris RE**, Dong E Jr., Struthers CM, Griep RB, Stinson EB, Billingham ME, and Shumway NE: Immunologic detection of human cardiac rejection, *Surgical Forum*, 25:282-284, 1974.
7. **Morris RE**, Souther S.G., Dong E Jr., Vistnes L.M., and Shumway N.E.: Prolongation of rat cardiac allograft survival by a new immunosuppressant: Chicken anti-rat lymphocyte globulin. *Surgery*, 76:150-159, 1974.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

8. **Morris RE**, Souther SG, Dong E Jr. and Shumway NE: Chicken antilymphocyte globulin: Mechanisms of action. *Transplant. Proc.*, 7:427-429, 1975.
9. Souther SG, **Morris RE**, and Vistnes LM: Trapping, splenectomy and allograft survival. *J. Immunol. (Letter to Editor)*, 114:1138, 1975.
10. **Morris RE**, and Dong E. Jr.: Clarification of certain characteristics of chicken antilymphocyte globulin. *Transplantation (Letter to Editor)*, 21:511-512, 1976.
11. **Morris RE**, Dong E Jr., and Shumway NE: Chicken anti-rat lymphocyte globulin (CARLG): Dose response study. *Surgical Forum*, 27:327-330, 1976.
12. **Morris RE**: High-efficiency differential ultracentrifugation of small sample volumes using Sorvall TFT-80.4 and TFT-80.2 rotors. *Biotechnology Update*, 3:11-12, 1988.
13. **Morris RE**, Hanley JM, Griep RB, and Shumway NE: Chicken antilymphocyte globulin: A source of heterologous enhancing antibody. *Transplant. Proc.*, 9:1037-1039, 1977.
14. **Morris RE**, Dong E Jr., Struthers CM, Griep RB and Stinson EB: Immunologic monitoring of cardiac transplant recipients by a modified reactive leukocyte blastogenesis assay (MRLB). *Transplant. Proc.*, 10:585-588, 1978.
15. **Morris RE**: Chicken anti-rat lymphocyte globulin: Dose-response study and determination of strain specific alloantibody. *Transplantation*, 28:77-83, 1979.
16. **Morris RE**: Chicken anti-rat lymphocyte globulin (CARLG): A new specific immunosuppressant. *Current Surgery*, 36:356-359, 1979.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

17. **Morris RE:** Sources of noncomplement-binding xenoantibody for passive enhancement of allografts. *Transplantation*, 34:157-159, 1982.
18. **Morris RE, Thomas PT and Hong R.:** Cellular enzyme-linked immunospecific assay (CELISA). A new micromethod that detects antibodies to cell-surface antigens. *Human Immunology*, 5:1-19, 1982.
19. **Morris RE:** A new, highly sensitive assay for quantitating antibody bound to cell-surface antigens. *Transplant. Proc.*, 15:60-62, 1983.
20. **Morris RE:** The induction of tolerance to and the definition of the pharmacokinetics of chicken anti-rat lymphocyte globulin. *Current Surgery*, 40:448-451, 1983.
21. **Morris RE:** Cellular enzyme-linked immunospecific assay. Use of the CELISA to quantitate monoclonal antibodies bound to HLA antigens and to sub-set specific antigens on cell surfaces. *Transplantation*, 36:719-725, 1983.
22. **Morris RE and Horowitz DA:** Cellular enzyme linked immunospecific assay (CELISA). Inhibition of endogenous cellular alkaline phosphatase activity. *J. Immunol. Methods*, 68:11-17, 1984.
23. **Morris RE:** Progress in the use of the cellular enzyme linked immunospecific assay (CELISA) for the phenotyping of cellular antigens associated with subpopulation of T-cells. *Review of Immunology and Immunopharmacology (EOS)*, 4:47-53, 1984.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

24. Anderson JE, **Morris RE** and Blaschke TE: Pharmacodynamics of cyclosporine-ketoconazole interaction in mice: Combined therapy potentiates cyclosporine immunosuppression and toxicity. *Transplantation*, 43:529-533, 1987.
25. **Morris RE**, DeValeria P, Skogen B, Pratt F, Cheng P-J, Kim J and Clark WA: Intravenously injected anti-cardiac myosin monoclonal antibody specifically demarcates cardiac rejection. *Transplant. Proc.*, 29:1053-1055, 1987.
26. **Morris,RE**, Hoyt,G. and DeValeria,P. A comparison in the in vitro and in vivo immunological activities of concanavalin A and its succinylated derivative. *Transplant. Proc.*, 29:626-627, 1987.
27. Cheng,P-J and **Morris,RE**: A new, rapid, high-capacity chromatographic purification of IgG 1 monoclonal antibodies directly from mouse ascites fluid. *Transplant. Proc.*, 29:607-609, 1987.
28. Anderson SE, **Morris RE** and Blaschke TE: Ketoconazole potentiates cyclosporine immunosuppression and toxicity in mice. *Transplant. Proc.*, 29:1267-1268, 1987.
29. Babany G, **Morris RE**, Babany I and Kates RE: Evaluation of the in vivo dose response relationship of immunosuppressive drugs using a mouse heart transplant model: Application to cyclosporine. *J. Pharmacol. and Exp. Therapeutics*, 244:259-262, 1988.
30. **Morris RE**, Hoyt G, Baldwin JC, and Meiser B.: Splenectomy antagonizes the action of cyclosporine. *Transplant. Proc.*, 20:1079-1080, 1988.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

31. Babany G, **Morris RE**, Babany I, Shepherd S, Kates R: In vivo evaluation of the effects of altered cyclosporine metabolism on its immunosuppressive potency. *J. Pharmacol. and Exp. Therapeutics*, 248:893-899, 1989.
32. **Morris RE**, Hoyt EG, Murphy MP, and Shorthouse R: Immunopharmacology of FK 506. *Transplant. Proc.*, 21:1042-1044, 1989.
33. Yuh D, Zurcher RP, Carmichael PG, **Morris RE**: Efficacy of Didemnin B therapy in suppressing allograft rejection in mice and rats. *Transplant. Proc.*, 21:1141-1143, 1989.
34. Gudas V, Carmichael PG, **Morris RE**: Comparison of the immunosuppressive and toxic effects of high dose oral FK-506 in the rat cardiac xenograft model. *Transplant. Proc.*, 21:1072-1073, 1989.
35. Carmichael PG, **Morris RE**: Alteration of in vivo allogeneic functions by ultraviolet B (UVB). *Transplant. Proc.*, 21:1137-1138. 1989.
36. **Morris RE** and Meiser B: A new pharmacologic action for an old compound Rapamycin. *Medical Science Research*, 17:609-610, 1989. (Republished due to typesetting errors, *Med. Sci. Res.* 17:877-878, 1989.)
37. **Morris RE**, Hoyt G, Eugui E and Allison A: Prolongation of rat heart allograft survival by RS-61443 Mycophenolace Mofetil. *Surgical Forum*, 40:337-338, 1989.
38. Meiser BM, Wang J, **Morris RE**: Rapamycin: A new and highly active immunosuppressive macrolide with efficacy superior to cyclosporine. *Progress in Immunology*, 7:1195-1198, 1989.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

39. Palladino MA, **Morris RE**, Starnes HF and Levinson AD: The transforming growth factor-betas: A new family of immunosuppressive molecules. *Ann. N.Y. Acad. Sci.*, 593:181-187, 1990.
40. **Morris RE**, Wu J, and Shorthouse R: Comparative immunopharmacological effects of FK506 and cyclosporine in in vivo models of organ transplantation. *Transplant. Proc.*, 22:(Suppl)1:110-112, 1990.
41. **Morris RE**, Wu J, and Shorthouse R: A study of the contrasting effects of cyclosporine, FK506 and rapamycin on the suppression of allograft rejection. *Transplant. Proc.*, 22:1638-1641, 1990.
42. **Morris RE**, Hoyt G, Murphy MP, Eugui EM, and Allison AC: Mycophenolic acid morpholinoethyl ester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T and B cell purine synthesis. *Transplant. Proc.*, 22:1659-1662, 1990.
43. **Morris RE**: Treating rejection of transplants in the post-cyclosporine era. *Dialysis and Transplant*, 19:544, 1990.
44. Wallick SC, Figari IS, **Morris RE**, Levinson AD and Palladino MA: Immunoregulatory role of transforming growth factor β (TGF- β) in development of killer cells: Comparison of active and latent TGF- β_1 . *J. Exp. Med.*, 172:1777-1784, 1990.
45. Meiser BM and **Morris RE**: The importance of the spleen for the immunosuppressive action of cyclosporine in transplantation. *Transplantation*, 51:690-696, 1991.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

46. **Morris RE**, Wang J: Comparison of the immunosuppressive effects of mycophenolic acid and the morpholinoethyl ester of mycophenolic acid (RS-61443) in recipients of heart allografts. *Transplant. Proc.*, 23:493-496, 1991.
47. **Morris RE**, Meiser BM, Wu J, Shorthouse R, and Wang J: Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK506, and effect on host-versus-graft and graft-versus-host reactions. *Transplant. Proc.*, 23:521-524, 1991
48. Zheng B, Shorthouse R, Masek MA, Berry G, Billingham ME and **Morris RE**: Effects of the new and highly active immunosuppressant, rapamycin, on lymphoid tissues and cells *in vivo*. *Transplant. Proc.*, 23:851-855, 1991
49. Wu J, Palladino MA, Figari IS, and **Morris RE**: Comparative immunoregulatory effects of rapamycin, FK506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation. *Transplant. Proc.*, 23:238-240, 1991.
50. Wang J, **Morris RE**: Effect of Splenectomy and mono- or combination therapy with rapamycin, the morpholinoethyl ester of mycophenolic acid and deoxyspergualin on cardiac xenograft survival. *Transplant. Proc.*, 23:699-702, 1991.
51. Flavin T, Ivens K, Wang J, Gutierrez J, Hoyt EG, Billingham M, **Morris RE**: Initial experience with FK506 as an immunosuppressant for nonhuman primate recipients of cardiac allografts. *Transplant. Proc.*, 23:531-532, 1991.
52. Yuh D, **Morris RE**: 15-Deoxyspergualin is a more potent and effective immunosuppressant than cyclosporine but does not effectively suppress lymphoproliferation *in vivo*. *Transplant. Proc.*, 23:535-539, 1991.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

53. **Morris RE**, Wang J, Blum J, Flavin T, Almquist SJ, Chu N, Lam YL, Kaloostian M, Allison A, and Eugui E: Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) on rat and non-human primate recipients of cardiac allografts. *Transplant. Proc.*, 23(Supp 2):19-25, 1991.
54. **Morris RE**: Rapamycin: FK506's fraternal twin or distant cousin? *Immunol. Today*, 12:137-140, 1991.
55. Meiser BM, Billingham ME, **Morris RE**: Effects of cyclosporine, FK506 and rapamycin on graft vessel disease. *The Lancet*, 338:1297-1298, 1991.
56. **Morris RE**: In vivo immunopharmacology of the macrolides FK506 and rapamycin: toward the era of rational immunosuppression drug discovery, development and use. *Transplantation Proceedings*, 23:2722-2724, 1991.
57. **Morris RE**: 15-Deoxyspergualin: a mystery wrapped within an enigma. *Clinical Transplant*, 5:530-533, 1991.
58. Murphy MP, **Morris RE**: Brequinar sodium (Dup 785) is a highly potent antimetabolite immunosuppressant that suppresses heart allograft rejection. *Medical Science Res.*, 19:835-836, 1991.
59. **Morris RE**: Rapamycins: antifungal, antitumor, antiproliferative and immunosuppressive macrolides. *Transplant Rev.*, 6:39-87, 1992.
60. **Morris RE**: Immunopharmacology of new xenobiotic immunosuppressive molecules. *Seminars in Nephrology*, 4:304-314, July 1992.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

61. Walpoth B, Galdikas J, Tschopp A, Lazeyras F, Altermatt HJ, Schaffner T, Althaus U, Billingham M and **Morris RE**: Prevention of cardiac allograft rejection by FK506 and rapamycin: assessment by histology and nuclear magnetic resonance. *Transplant. Intl.*, 5(Suppl 1):S561-S563, 1992.
62. Walpoth B, Galdikas J, Vorburger T, Altermatt HJ, Schaffner T, Althaus U, Billingham M, **Morris RE**: Assessment of new immunosuppressive drugs in a rat cardiac allograft heterotopic model. *Eur. J. Surg. Res.*, 24:243-248, 1992.
63. Mohacsi PJ, **Morris RE**: Brief treatment with rapamycin in vivo increases responsiveness to alloantigens measured by the mixed lymphocyte response. *Immunology Letters*, 34:273-278, 1992.
64. Yuh D and **Morris RE**: The immunopharmacology of immunosuppression by 15-deoxyspergualin. *Transplantation*, 55:578-591, 1993.
65. **Morris RE**: Prevention and treatment of allograft rejection in vivo by rapamycin: molecular and cellular mechanisms of immunosuppressive action. *Annals NY Acad. of Sci.*, 685:68-72, 1993.
66. **Morris RE**: Commentary on new xenobiotic immunosuppressants for transplantation: where are we, how did we get here, and where are we going? *Clinical Transplantation*, 7(Issue 1, Part 2):138-145, 1993.
67. Nakakura EK, McCabe SM, Zheng B, Shorthouse RA, Scheiner TM, Blank G, Jardieu PM, and **Morris RE**: Potent and effective prolongation by anti-LFA-1 monoclonal antibody monotherapy of non-primarily vascularized heart allograft

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

- survival in mice without T cell depletion. *Transplantation (Rapid Communication)*, 55:412-417, 1993.
68. Gregory CR, Huie P, Shorthouse R, Wang J, Rowan R, Billingham ME, **Morris RE**: Treatment with rapamycin blocks arterial intimal thickening following mechanical and alloimmune injury. *Transplant Proc.*, 25:120-121, 1993.
69. Gregory CR, Pratt RE, Huie P, Shorthouse R, Dzau VJ, Billingham ME, **Morris RE**: Effects of treatment with cyclosporine, FK506, rapamycin, mycophenolic acid or deoxyspergualin on vascular smooth muscle proliferation in vitro and in vivo. *Transplant Proc.*, 25:770-771, 1993.
70. Nakakura EK, McCabe SM, Zheng B, Shorthouse RA, Scheiner TM, Blank G, Jardieu PM, **Morris RE**: A non-lymphocyte depleting monoclonal antibody to the adhesion molecule LFA-1 (CD11a) prevents sensitization to alloantigens and effectively prolongs the survival of heart allografts. *Transplant Proc.*, 25:809-812, 1993.
71. Murphy M, **Morris RE**: Brequinar sodium effectively and potently suppresses allograft rejection in a heterotopic mouse heart transplant model. *Transplant Proc.*, 25(Supp 2):75-76, 1993.
72. Gregory CR, Huie P, Billingham ME, and **Morris RE**: Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury: effect on cellular growth factor and cytokine responses in injured vessels. *Transplantation (Rapid Communication)*, 55:1409-1418, 1993.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

73. **Morris RE:** New small molecule immunosuppressants for transplantation: review of essential concepts. *J. Heart and Lung Transplant*, 12:S275-S286, 1993.
74. **Morris RE:** Primer on new small molecule immunosuppressants: Emergency treatment for the confused and bewildered. *Transplantation Society Bulletin*, Issue No. 1:15-21, 1993.
75. Fealy MJ, Umansky WS, Bickel KD, Nino JJ, **Morris RE**, Press BHJ: Efficacy of rapamycin and FK506 in prolonging rat hind limb allograft survival: a comparative study. *Annals of Surgery*, 219:88-93, 1994.
76. Mohacsi PJ, Joshi A, Wang J, **Morris RE**, Billingham ME: Endocardial mononuclear cell infiltrates (Quilty Effect) in heterotopic cardiac allografts in rapamycin-treated rats. *Transplant Proc*, 26:3255-3259, 1994.
77. **Morris RE:** Modes of action of FK506, cyclosporin A, and rapamycin. *Transplant Proc*, 26:3272-3275, 1994.
78. Walpoth BH, Lazeyras F, Tschopp A, Schaffner T, Althaus U, Billingham M, **Morris RE:** Assessment of cardiac rejection and immunosuppression by magnetic resonance imaging and spectroscopy. *Transplant Proc.*, 1995, June, 27(3):2088-91.
79. Cao W, Mohacsi PJ, Pratt RE, **Morris RE:** Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell proliferation: inhibition of bFGF and PDGF action and antagonism of rapamycin by FK506. *Transplantation*, 59:390-395, 1995.
80. **Morris RE** Huang X, Cao W, Zheng B, Shorthouse RA: Leflunomide (HWA 486) and its analogs suppress T and B cell proliferation in vitro, acute rejection, ongoing

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

- rejection, and anti-donor antibody synthesis in mouse, rat and cynomolgus monkey transplant recipients, as well as arterial intimal thickening after balloon catheter injury. *Transplant Proc*, 27:445-447, 1995.
81. **Morris RE**, Cao W, Huang X, Gregory CR, Billingham, MR, Rowan R, Shorthouse RA: Rapamycin (sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells. *Transplant Proc*, 27:430-431, 1995.
82. Gregory CR, Huang X, Pratt RE, Dzau V, Billingham ME, **Morris RE**: Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening after balloon catheter injury and allows endothelial replacement. *Transplantation (Rapid Communication)*, 59:655-661, 1995.
83. Fealy MF, Most D, Huie P, Wolf M, Sibley, RK, **Morris RE**, Press BHJ: Association of down-regulation of cytokine activity with rat hind limb allograft survival. *Transplantation* 59:1475-1480, 1995.
84. **Morris RE**, Huang X, Gregory CR, Billingham ME, Rowan R, Shorthouse R, Berry G: Studies in experimental models of chronic rejection: use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analog) for the suppression of graft vascular disease and obliterative bronchiolitis. *Transplant Proc*, 27:2068-2069, 1995.
85. Nair RV, **Morris RE**: Immunosuppression in cardiac transplantation: a new era in immunopharmacology. *Current Opinion in Cardiol*, 10:207-217, 1995.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

86. Galili U, Gregory CR, **Morris RE**: Contribution of anti-gal antibodies to primate and human IgG binding to porcine endothelial cells. *Transplantation*, 60:210-213, 1995.
87. **Morris RE**, Brown BW Jr.: Tacrolimus for prevention of liver allograft rejection: clinical trials and tribulations. *The Lancet*, 346:1310-1311, 1995.
88. Nair RV, Cao W, **Morris RE**: Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine. *Immunol Letters*, 1995; 47(3):171-174.
89. Yuh DD, Gandy KL, **Morris RE**, Hoyt G, Gutierrez J, Reitz BA, Robbins RC: Leflunomide prolongs lung allo- and xenograft survival. *J Heart and Lung Transplant*, 14:1136-44, 1995.
90. Reichenspurner H, Huang X, Adams B., Soni V, Shorthouse R, Reitz BA, Berry GJ, **Morris RE**: Pathogenesis and treatment of obliterative airway disease after heterotopic tracheal allograft and xenograft transplantation. *Surgical Forum*, 46:456-8, 1995.
91. **Morris RE**: Mechanisms of action of new immunosuppressants. *Therapeutic Drug Monitoring*, 17:564-569, 1995.
92. Reichenspurner H, Girgis RE, Robbins RC, Conte JV, Nair R, Valentine V, Berry GJ, **Morris RE**, Theodore J, Reitz BA: Review of the pathogenesis, diagnosis and management of obliterative bronchiolitis after lung- and heart-lung transplantation - a 14 year experience in 163 patients. *Annals of Thoracic Surgery*, 60:1845-53, 1995.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

93. Cao WE, Kao PN, Chao AC, Gardner P, Ng J, **Morris RE**: Mechanism of the anti-proliferative action of leflunomide: A771726, the active metabolite of leflunomide, does not block T cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides. *J Heart Lung Transp*, 14:1016-30, 1995.
94. Galili U, Gregory CR, **Morris RE**: New World monkeys as a primate model for xenografts in the absence of anti-Gal antibodies. *Transpl Proc* 28:567-568, 1995.
95. Shaw LM, Sollinger HW, Halloran P, **Morris RE**, et al: Mycophenolate mofetil: A report of the consensus panel. *Therap Drug Monitoring*, 17(6):690-699, 1995.
96. Reichenspurner H, Girgis RE, Robbins RC, Conte JV, Nair RV, Valentine V, Berry GJ, **Morris RE**, Theodore J, Reitz BA: Obliterative bronchiolitis after lung and heart-lung transplantation. *Annals of Thoracic Surgery*, 60:1845-1853, 1995.
97. **Morris RE**: Mechanisms of Action of New Immunosuppressive Drugs. *Kidney International*, 49(Suppl 53):S-26-S-38, 1996.
98. Lirtzman RA, Gregory CR, Levitski RE, Griffey SM, Yeh L-S, Patz JD, **Morris RE**: Combined immunosuppression with leflunomide and cyclosporine prevents MLR-mismatched renal allograft rejection in a mongrel canine model. *Transplantation Proceedings*, 28(2): 945-947, 1996.
99. Reichenspurner H, Adams B, Soni V, Brazelton T, Shorthouse R, Reitz BA, Berry GJ, and **Morris RE**: Obliterative airway disease (OAD) after heterotopic tracheal xenotransplantation in a concordant rodent model: pathogenesis and treatment. *Transplantation Proceedings*, 28(2): 729-730, 1996.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

100. Nair RV, **Morris RE**: New immunosuppressive strategies in renal transplantation: new answers to old questions. *Current Opinion in Organ Transplantation*, 1:8-21, 1996.
101. Suthanthiran M, **Morris RE**, Strom, T.B.: Immunosuppressants: Cellular and molecular mechanisms of action. *American Journal of Kidney Diseases*, 28: 159-172, 1996.
102. Nakakura EN, Shorthouse R, Zheng B, McCabe S, Jardieu P, **Morris RE**: Prolongation of heart allograft survival by anti-LFA-1 monoclonal antibody monotherapy: mechanisms of induction of antigen-specific unresponsiveness. *Transplantation*, 62: 547-552, 1996.
103. Gregory CR, Cooke JP, Patz JD, Berryman ER, Shorthouse R, **Morris RE**: Enhanced nitric oxide production induced by the administration of L-arginine does not inhibit arterial neointimal formation after overwhelming alloimmune injury. *J. of Heart and Lung Transplantation*, 15: 58-66, 1996.
104. Brazelton TR, **Morris RE**: Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: Tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil, and leflunomide. *Current Opinion in Immunology*, 8:710-720, 1996.
105. Silva HT, Cao W, Shorthouse R, **Morris RE**: Mechanisms of action of leflunomide: In vivo uridine administration reverses its inhibition of lymphocyte proliferation. *Transplantation Proceedings*, 28: 3082-3084, 1996.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

106. Goldman ME, Ransone LJ, Anderson DW, Gaarde QA, Suto MJ, Sullivan RW, Shorthouse R, Morikawa M, **Morris RE**: SP100030 is a novel T-cell-specific transcription factor inhibitor that possesses immunosuppressive activity in vivo. *Transplantation Proceedings*, 28:3106-3109, 1996.
107. Cao W, Kao PN, Aoki Y, Xu JC, Shorthouse R, **Morris RE**: A novel mechanism of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF β 1, and suppression of the immunostimulatory cytokine, IL-2. *Transplantation Proceedings*, 28:3079-3080, 1996.
108. Reichenspurner H, Girgis R, Robbins R, Yun K, Nitschke M, Berry G, **Morris RE**, Theodore J., Reitz B.A.: Stanford experience with obliterative bronchiolitis after lung- and heart-lung transplantation. *Annals of Thoracic Surgery*, 62:1467-1473, 1996.
109. Silva HT, Shorthouse R, **Morris RE**: Single- and multiple-dose pharmacokinetics and pharmacodynamics of leflunomide's active metabolite A771726 in normal Lewis rats. *Transplantation Proceedings*, 28:3092-3094, 1996.
110. Nair RV, Cao W, **Morris RE**: The antiproliferative effects of leflunomide on vascular smooth muscle cells in vitro is mediated by selective inhibition of pyrimidine biosynthesis. *Transplantation Proceedings*, 28:3081, 1996.
111. **Morris RE**: Beware: Shifting Paradigms Ahead. *Lancet*, 348 (suppl II), 26, 1996.
112. Yeh L-S, Gregory CR, Griffey SM, Lecouteur RA, and **Morris RE**: Effects of leflunomide and cyclosporine on myocutaneous allograft survival in the rat. *Transplantation* 62, 6, 1996.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

113. Fahrni JA, **Morris RE**, Rosen GD: Rapamycin inhibits the development of obliterative airway disease in a murine heterotopic airway transplant model. *Transplantation*. 63(4):533-7, 1997.
114. Silva HT, **Morris RE**: Leflunomide and malononitriloamides. *Exp. Opin. Invest. Drugs* 6:51-64, 1997.
115. Morikawa M, Shorthouse RA, Suto MJ, Goldman ME, **Morris RE**: A novel inhibitor of nuclear factor- κ B and activator protein-1 transcription factors in T cells suppresses host-versus-graft alloreactivity in vivo. *Transplantation Proceedings*, 29:1269-70, 1997.
116. Nair RV, Huang X, Shorthouse R, Adams B, Brazelton T, Braun-Dullaeus R, **Morris RE**: Antiproliferative effects of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo. *Transplant Proceedings*, 29(1-2):614-615, 1997.
117. Silva HT, **Morris RE**: Leflunomide and malononitrilamides. *American Journal of Medical Sciences*. 313(5):289-301, 1997.
118. Yeh L-S, Gregory CR, Griffey SM, Lecouter RA, **Morris RE**: Combination of leflunomide and cyclosporine prevents rejection of functional whole limb allografts in rats. *Transplantation* 64(6):919-22, 1997
119. Ikonen T, Uusitalo M, Taskinen E, Korpela A, Salminen U-S, **Morris RE**, Harjula ALJ: A new large-animal heterotopic lung and bronchial allograft model for research of obliterative bronchiolitis. *Transplantation Proceedings*, 29(6):2611-2, 1997.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

120. Metcalfe SM, Canman CE, Milner J, **Morris RE**, Goldman S, Kastan MB: Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells. *Oncogene* 15(14):1635-42, 1997.
121. Hausen B, Mueller P, Bahra M, Ramsamooj R, **Morris RE**, Hewitt CW: Donor treatment with the lazeroid U74389G reduces ischemia-reperfusion injury in a rat lung transplant model. *Annals of Thoracic Surgery*, 64(3):814-20, 1997.
122. Hausen B, **Morris RE**: Review of Immunosuppression for lung transplantation. Novel drugs, new uses for conventional immunosuppressants, and alternative strategies. *Clinics in Chest Medicine*. 18(2):353-66, 1997.
123. Reichenspurner H, Soni V, Nitschke M, Berry G, Brazelton TR, Shorthouse R, Huang X, Reitz B, **Morris RE**: Obliterative airway disease after heterotopic tracheal xenotransplantation-pathogenesis and prevention using new immunosuppressive agents. *Transplantation* 64(3):373-83, 1997.
124. Briffa N, **Morris RE**: New immunosuppressive regimens in lung transplantation. *European Respiratory Journal*, 10(11):2630-37, 1997.
125. Cheung A, Billingham M, Sherwood S, Brazelton T, Shorthouse R, and **Morris RE**: Leflunomide Abrogates Accelerated Heart Allograft Rejection in Presensitized Rats. *Transplantation Proceedings*, 29, 1294-1295, 1997.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

126. Salminen US, Uusitalo M, Ikonen T, Taskinen E, **Morris RE**, Harjula ALJ: Effect of immunosuppression on obliterative lesions in a heterotopic large-animal bronchial allograft model. *Transplantation Proceedings*, 29:7, 3155-56, 1997.
127. Silva HT Jr., Cao W, Shorthouse RA, Loffler M, **Morris RE**: In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis, *Transplantation Proceedings*. 29(1-2).1997. 1292-1293.
128. Reichenspurner H, Soni V, Nitschke M, Brazelton T, Shorthouse R, Boname J, Adams B, Girgis R, Reitz BA, Mocarski E, Sandford G, Berry G, **Morris RE**: Enhancement of obliterative airway disease (OAD) in rat tracheal allografts infected with recombinant rat cytomegalovirus. *Journal of Heart & Lung Transplantation*. 17(5):439-51, 1998.
129. Gregory CR, Galili U, Hancock WW, Valverde CR, Griffey SM, Berryman ER, **Morris RE**: Squirrel monkeys hyperacutely reject porcine musculocutaneous flaps despite a lack of naturally occurring xenoantibodies. *Transplantation Proceedings*. 30(4):1082-3, 1998.
130. Dosanjh AK, Wan B, Thronset W, Sherwood S, **Morris RE**: Pirfenidone: a novel antifibrotic agent with implications for the treatment of obliterative bronchiolitis. *Transplantation Proceedings*. 30(5):1910-1, 1998.
131. Gregory CR, Stewart A, Sturges B, DeManville T, Cannon A, Ortega T, Harb M, **Morris RE**: Leflunomide effectively treats naturally occurring immune-mediated and inflammatory diseases of dogs that are unresponsive to conventional therapy. *Transplantation Proceedings*. 30(8):4143-8, 1998.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

132. Ikonen T, Uusitalo M, Taskinen E, Korpela A, Salminen US, **Morris RE**, Harjula AL: Small airway obliteration in a new swine heterotopic lung and bronchial allograft model. *Journal of Heart & Lung Transplantation*; 17(10):945-53, 1998.
133. Shaw LM, Nicholls A, Hale M, Armstrong VW, Oellerich M, Yatscoff R, **Morris RE**, Holt DW, Venkataramanan R, Haley J, Halloran P, Ettenger R, Keown P, **Morris, REG**: Therapeutic monitoring of mycophenolic acid. A consensus panel report. *Clinical Biochemistry*. 31(5):317-22, 1998.
134. Hausen B, Bahra M, Mueller P, Poets CF, Hewitt CW, **Morris RE**: Donor pretreatment with ambroxol or dexamethasone fails to ameliorate reperfusion injury in experimental lung transplantation. *Transplantation International*. 11(3):186-94, 1998.
135. Hausen B, Ikonen T, Berry G, Hook L, and **Morris RE**: Noninvasive monitoring of pulmonary arterial pressure by telemetry for long-term assessment of graft function following lung transplantation. *Surgical Forum*, 59, 366-69, 1998.
136. Gregory CR, Silva HT, Patz JD, **Morris RE**: Comparative effects of malononitriloamide analogs of leflunomide on whole blood lymphocyte stimulation in humans, rhesus macaques, cats, dogs, and rats. *Transplantation Proceedings*. 30(4):1047-8, 1998.
137. Briffa N, **Morris RE**: Immunosuppressive drugs after lung transplantation. *British Medical Journal*. 316 (7133):719-20, 1998.
138. Gummert JF, Ikonen T, Briffa, Honda Y, Hayase M, Perlroth J, Kobayashi Y, Hausen Barlow C, Billingham ME, Fitzgerald, Yock P, Robbins RC, **Morris, RE**: A new

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

- large-animal model for research of graft vascular disease. *Transplantation Proceedings*. 30(8):4023, 1998.
139. Segarra I, Brazelton TR, Guterman N, Hausen B, Jacobsen W, **Morris RE**, Benet LZ, Christians U: Development of a high-performance liquid chromatographic-electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2-hydroxyethyl)rapamycin. *Journal of Chromatography*. 720(1-2):179-87, 1998.
140. Gummert JF, Christians U, Barten M, Silva H, **Morris RE**: High-performance liquid chromatographic assay with a simple extraction procedure for sensitive quantification of mycophenolic acid in rat and human plasma. *Journal of Chromatography*. 721(2):321-6, 1999.
141. Hausen B, Boeke K, Berry GJ, Segarra IT, Christians U, **Morris RE**: Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. *Journal of Heart & Lung Transplantation*. 18(2):150-9, 1999.
142. Ikonen TS, Romanska HM, Bishop AE, Berry GJ, Polak JM, **Morris RE**: Alterations in inducible nitric oxide synthase (iNOS) and nitrotyrosine (NitroY) during re-epithelialization of heterotopic rat tracheal composite grafts. *Transplantation Proceedings*. 31(1-2):182, 1999.
143. Jeremias A, Kolz ML, Ikonen TS, Jan F, Gummert JF, Oshima A, Hayase M, Komiyama M, Berry GJ, **Morris RE**: Yock, PG, Fitzgerald PJ: Feasibility of in vivo

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

- intravascular ultrasound tissue characterization in the detection of early vascular transplant rejection. *Circulation*, 100(21):2127-30, 1999.
144. Brazelton TR, Adams B, Shorthouse R, **Morris RE**: Chronic rejection: the result of uncontrolled remodeling of graft tissue by recipient mesenchymal cells? Data from two rodent models and the effects of immunosuppressive therapies. *Inflammation Research.*; 48 Suppl 2:S134-5, 1999.
145. Slauson S, Billingham ME, Silva HT, Wang Y, **Morris RE**: Quilty effect in heterotopic cardiac allografts in malononitriloamide-treated rats. *Journal of Heart & Lung Transplantation*;18(12):1251-3, 1999.
146. Fox RI, Herrmann ML, Frangou CG, Wahl GM, **Morris RE**, Strand V, Kirschbaum BJ: Mechanism of action for leflunomide in rheumatoid arthritis. *Clinical Immunology*; 93(3):198-208, 1999.
147. Gummert JF, Barten MJ, Sherwood SW, van Gelder T, **Morris RE**: Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. *Journal of Pharmacology & Experimental Therapeutics*; 291(3):1100-12, 1999.
148. Hausen B, Berry GJ, Dagum P, Ikonen T, Christians U, Briffa N, Hook L, **Morris RE**: The histology of subcutaneously implanted donor bronchial rings correlates with rejection scores of lung allografts in a primate lung transplant model. *Journal of Heart & Lung Transplantation*; 18(7):714-24, 1999.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

149. Poston RS, Billingham M, Hoyt EG, Pollard J, Shorthouse R, **Morris RE**, Robbins RC: Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. *Circulation*. 100(1):67-74, 1999.
150. Slauson SD, Silva HT, Sherwood SW, **Morris RE**: Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitriloamide analogues in a novel whole blood assay. *Immunology Letters*; 67(3):179-83, 1999.
151. Gummert JF, Ikonen T, **Morris RE**: Newer immunosuppressive drugs: a review. *Journal of the American Society of Nephrology*;10(6):1366-80, 1999.
152. Gummert JF, Otto G, Barten MJ, **Morris RE**: Effect of anesthesia on a whole blood lymphocyte proliferation assay in the rat. *Immunopharmacology & Immunotoxicology*; 21(2):267-76, 1999.
153. Ikonen TS, Gummert JF, Honda Y, Hayase M, Perloth J, Hausen B, Barlow C, Fitzgerald P, Yock PG, **Morris RE**: Development of models of graft vascular disease (GVD) in nonhuman primates: evaluation of GVD by intravascular ultrasound. *Transplantation Proceedings*; 31(1-2):687, 1999.
154. Hausen B, Boeke K, Berry GJ, Gummert JF, Christians U, **Morris RE**: Potentiation of immunosuppressive efficacy by combining the novel leflunomide analog, HMR 279, with microemulsion cyclosporine in a rat lung transplant model. *Transplantation*; 67(3):354-9, 1999.
155. Hausen B, Boeke K, Berry GJ, Segarra I, Benet LZ, Christians U, **Morris RE**: Coadministration of Neoral® and the novel rapamycin analog, SDZ RAD, to rat lung

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

- allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. *Transplantation*; 67(7):956-62, 1999.
156. Rubin RH, Ikonen T, Gummert JF, and **Morris RE**: The therapeutic prescription for the organ transplant recipient: The linkage of immunosuppression and antimicrobial strategies. *Transplant Infectious Disease*, 1:1, 29-39, 1999.
157. Hausen B, Ikonen T, Briffa N, Berry GJ, Christians U, Robbins RC, Hook L, Serkova N, Benet LZ, Schuler W, **Morris RE**: Combined immunosuppression with cyclosporine (Neoral®) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability. *Transplantation*; 69(1):76-86, 2000.
158. Chen BJ, **Morris RE**, Chao NJ: Graft-versus-host disease prevention by rapamycin: cellular mechanisms. *Biology of Blood, Marrow & Transplants*. 6(5A):529-36, 2000.
159. Dambrin C, Klupp J, **Morris RE**: Pharmacodynamics of immunosuppressive drugs. *Current Opinion in Immunology*; 12(5):557-62, 2000.
160. Serkova N, Hausen B, Berry GJ, Jacobsen W, Benet LZ, **Morris RE**, Christians U: Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine. *Journal of Pharmacology & Experimental Therapeutics*; 294(1):323-32, 2000.
161. Hausen B, Gummert J, Berry GJ, Christians U, Serkova N, Ikonen T, Hook L, Legay F, Schuler W, Schreier MH, **Morris RE**: Prevention of acute allograft rejection

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

- in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin. *Transplantation*; 69(4):488-96, 2000.
162. Adams BF, Brazelton T, Berry GJ, **Morris RE**: The role of respiratory epithelium in a rat model of obliterative airway disease. *Transplantation*; 69(4):661-4, 2000.
163. Poston RS, Robbins RC, Chan B, Simms P, Presta L, Jardieu P, **Morris RE**: Effects of humanized monoclonal antibody to rhesus CD11a in rhesus monkey cardiac allograft recipients. *Transplantation*; 69(10):2005-13, 2000.
164. Adams BF, Berry GJ, Huang X, Shorthouse R, Brazelton T, **Morris,RE**: Immunosuppressive therapies for the prevention and treatment of obliterative airway disease in heterotopic rat trachea allografts. *Transplantation*; 69(11):2260-6, 2000.
165. Ikonen TS, Briffa N, Gummert JF, Honda Y, Hayase M, Hausen B, Billingham ME, Yock PG, Robbins RC, **Morris RE**: Multidimensional assessment of graft vascular disease (GVD) in aortic grafts by serial intravascular ultrasound in rhesus monkeys. *Transplantation*; 70(3):420-9, 2000.
166. Ikonen TS, Brazelton TR, Berry GJ, Shorthouse RS, **Morris RE**: Epithelial re-growth is associated with inhibition of obliterative airway disease in orthotopic tracheal allografts in non-immunosuppressed rats. *Transplantation*; 70(6):857-63, 2000.
167. Romanska HM, Ikonen TS, Bishop AE, **Morris RE**, Polak JM: Up-regulation of inducible nitric oxide synthase in fibroblasts parallels the onset and progression of

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

- fibrosis in an experimental model of post-transplant obliterative airway disease. *Journal of Pathology*;191(1):71-7, 2000.
168. Ikonen, TS, Gummert, JF, Serkova, N, Hayase, M, Honda, Y, Kobayase, Y, Hausen, B, Yock, PG, Christians, U, **Morris RE**: Efficacies of sirolimus (rapamycin) and cyclosporine in allograft vascular disease in non-human primates: Trough levels of sirolimus correlate with inhibition of progression of arterial intimal thickening. *Transplant Intl.*; 13 (Suppl 1): S314-20, 2000.
169. Duane DD, Monroe J, **Morris RE**: Mycophenolate in the prevention of recurrent neutralizing botulinum toxin A antibodies in cervical dystonia. *Movement Disorders*;15(2):365-6, 2000.
170. Hausen B, Boeke K, Berry GJ, Christians U, Schuler W, **Morris RE**: Successful treatment of acute, ongoing rat lung allograft rejection with the novel immunosuppressant SDZ-RAD. *Annals of Thoracic Surgery*; 69(3):904-9, 2000.
171. Serkova N, Litt L, Leibfritz D, Hausen B, **Morris RE**, James TL, Benet LZ, Christians U: The novel immunosuppressant SDZ-RAD protects rat brain slices from cyclosporine-induced reduction of high-energy phosphates. *British Journal of Pharmacology*; 129(3):485-92, 2000.
172. Ikonen TS, Gummert JF, Hayase M, Honda Y, Hausen B, Christians U, Berry GJ, Yock PG, **Morris RE**: Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. *Transplantation*; 70(6):969-75, 2000.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

173. Gummert JF, Barten MJ, van Gelder T, Billingham ME, **Morris RE**: Pharmacodynamics of mycophenolic acid in heart allograft recipients: correlation of lymphocyte proliferation and activation with pharmacokinetics and graft histology. *Transplantation*; 70(7):1038-49, 2000.
174. **Morris RE**: Immunosuppression for transplantation. *Current Opinion in Anti-inflammatory & Immunomodulatory Investigational Drugs*. 2(4):275, 2000.
175. Serkova N, Hausen B, Berry GJ, Jacobsen W, Benet LZ, **Morris RE**, Christians U: Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: Interaction with cyclosporine, *Journal of Pharmacology & Experimental Therapeutics*. 294(1), 2000. 323-332.
176. Doyle RL, Hertz MI, Dunitz JM, Loyd JE, Stecenko AA, Wong RL, Chappell KA, Brazelton T, Kovarik JM, Appeldingemane S, Dou L, Smith HT, Tudor D, and **Morris RE**: RAD in stable lung and heart/lung transplant recipients: Safety, tolerability, pharmacokinetics, and impact of cystic fibrosis. *Journal of Heart & Lung Transplantation*, 20:3, 330-39, 2001.
177. Morikawa M, Brazelton T, Berry GJ, **Morris RE**: Prolonged inhibition of obliterative airway disease in murine tracheal allografts by brief treatment with anti-LFA-1 (CD11a) monoclonal antibody. *Transplantation*. 71(11), 2001. 1616-1621.
178. Klupp J, Van Gelder T, Dambrin C, Regieli J, Boeke K, Billingham ME, **Morris RE**. Mycophenolate mofetil pharmacodynamics and pharmacokinetics correlate with

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

- rejection score in a BN to LEW heterotopic heart transplant model. *Transplantation Proceedings*. 33(3), 2001. 2170-2171.
179. Van Gelder T, Klupp J, Barten MJ, Christians U, and **Morris RE**: Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. *Therapeutic Drug Monitoring*. 23(2), 2001. 119-128.
180. Walpoth BH, Pavlicek M, Celik B, Nicolaus B, Schaffner T, Althaus U, Hess OM, **Morris RE**: Prevention of neointimal proliferation by immunosuppression in synthetic vascular grafts. *European Journal of Cardio-Thoracic Surgery*, 19, 487-492, 2001.
181. Hausen B, Klupp J, Christians U, Higgins JP, Baumgartner RE, Hook LE, Friedrich S, Celnicker A and **Morris RE**: Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD 86 successfully prolong allograft survival times after life supporting renal transplantation in cynomolgus monkeys. *Transplantation* 72 (6): 1128-37, 2001.
182. **Morris RE**: Vascular and cellular mechanisms of chronic renal allograft dysfunction. *Transplantation* 71 (11 supplement): SS 37-41, 2001.
183. Hausen B, Boeke K, Berry GJ and **Morris RE**: Viral serine proteinase inhibitor (SERP-1) effectively decreases the incidence of graft vasculopathy in heterotopic heart allografts. *Transplantation* 72 (3): 364-8, 2001.
184. Braun-Dullaeus RC, Mann MJ, Seay U, Zhang L, Von Der Leyen HE, **Morris RE** and Dzau VJ: Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. *Arteriosclerosis, Thrombosis and Vascular Biology* 21 (7): 1152-8, 2001.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

185. Van Gelder T, Klupp J, Sawamoto T, Christians U and **Morris RE**: ATP-binding cassette transporters and calcineurin inhibitors: potential clinical applications. *Transplantation proceedings* 33(3): 2420-1, 2001.
186. Barten MJ, van Gelder T, Gummert JF, Shorthouse R, Boeke K, Billingham ME and **Morris RE**: New mechanisms of action of mycophenolate mofetil in transplant recipients by assessment of its pharmacodynamics. *Transplantation Proceedings* 33 (3): 2254-5, 2001.
187. Klupp J, Dambrin C, Regieli J, Van Gelder T, Shorthouse R and **Morris, RE**: New approach in drug development: whole blood pharmacodynamic assays reflect biological activities of tacrolimus. *Transplantation Proceedings* 33 (3): 2172, 2001.
188. Klupp J, Van Gelder T, Dambrin C, Regieli J, Boeke K, Billingham ME and **Morris RE**: Mycophenolate mofetil pharmacodynamics and pharmacokinetics correlate with rejection score in a BN-to-LEW heterotopic heart transplant model. *Transplantation Proceedings* 33(3): 2170-1, 2001.
189. Barten MJ, Gummert JF, Van Gelder T, Shorthouse R and **Morris RE**: Assessment of mechanisms of action of immunosuppressive drugs using novel whole blood assays. *Transplantation Proceedings* 33(3):2119-20, 2001.
190. Barten MJ, Gummert JF, Van Gelder T, Shorthouse R and **Morris RE**: Flow cytometric quantitation of calcium-dependent and independent mitogen-stimulation of T cell functions in whole blood: inhibition by immunosuppressive drugs in vitro. *Journal of Immunological Methods* 253(1-2):95-112, 2001.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

191. Jacobsen W, Serkova N, Hausen B, **Morris RE**, Benet LZ, Christians U: Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD, Transplantation Proceedings. 33(1-2), 2001. 514-515.
192. Vriens PW, Pollard JD, Hoyt G, **Morris RE**, Scheringa M, Bouwman E, Robbins RC: Hamster cardiac xenografts are protected against antibody mediated damage, early after transplantation to Lewis rats. Xenotransplantation 8(4):239-46, 2001.
193. Dosanjha A, Wan B, Ikonen T, Boeke K, **Morris RE**: Airway goblet cells and respiratory epithelial injury in an animal model of obliterative airways disease (OAD). Am J Transplant. 2001 Nov;1(4):321-324
194. Dosanjha A, **Morris RE**, Wan B: Bronchial epithelial cell-derived cytokine IL-10 and lung fibroblast proliferation. Transplant Proc. 2001 Feb-Mar; 33(1-2):352-354. No abstract available
195. Kyles AE, Gregory CR, Griffey SM, Galvez J, Ramsamooj R, **Morris RE**: Evaluation of the clinical and histologic features of renal allograft rejection in cats. Vet Surg. 31(1):49-56, 2002.
196. Barten MJ, van Gelder T, Gummert JF, Boeke K, Shorthouse R, Billingham ME, **Morris RE**: Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection, American Journal of Transplantation 2002 (2):719-32.
197. Dosanjh A, Ikonen T, Wan B, **Morris RE**: Pirfenidone: A novel anti-fibrotic agent and progressive chronic allograft rejection. Pulmonary Pharmacology & Therapeutics. 15(5).2002. 433-437.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

198. Barten MJ, van Gelder T, Gummert JF, Shorthouse R, **Morris RE**: Novel assays of multiple lymphocyte functions in whole blood measure new mechanisms of action of mycophenolate mofetil in vivo. *Transplant Immunology* 10(1) 1-14, 2002.
199. Borie DC, Hausen B, Larson M, Klupp J, Stalder M, Birsan T, **Morris, RE**: A life-supporting technique of renal allotransplantation in macaca fascicularis to evaluate
200. Lam TT, Hausen B, Squires E, Cozzi E, **Morris RE**: Cyclophosphamide induced postoperative anemia in cynomolgus monkey recipients of hDAF-transgenic pig organ xenografts. *Transpl Proc* 2002; 34: 1451-1452.
201. Kyles AE, Gregory CR, Griffey SM, Jackson J, Bernsteen L, **Morris RE**: An evaluation of combined immunosuppression with MNA 715 and microemulsified cyclosporine on renal allograft rejection in mismatched mongrel dogs. *Vet surg.* 2002 Jul-Aug;31(4):358-366
202. Singer LG, Brazelton TR, Doyle RL, **Morris RE**, Theodore J: Weight gain after lung transplantation. *J Heart Lung Transplant.* 2003 Aug, 22(8): 894-902
203. Kyles AE, Gregory CR, Griffey SM, Bernsteen L, Pierce J, Kilia HS, **Morris RE**: Modified noble plication for the prevention of intestinal intussusception after renal transplantation in dogs. *J Invest Surg.* 2003 May-June; 16(3): 161-166
204. Kyles AE, Gregory CR, Griffey SM, Bernsteen L, Pierce J, Lilja HS, **Morris RE**: Immunosuppression with a combination of the leflunomide analog, FK778, and microemulsified cyclosporine for renal transplantation in mongrel dogs. *Transplantation.* 2003 April 27;75(8): 1128-1133

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

205. Lam TT, Borie DC, Masek M, Berry G, Larson M, **Morris RE**: Graft thrombosis in hDAF-transgenic pig hearts transplanted into Rhesus monkeys. *Xenotransplantation*, 2003;0:185-186.
206. Borie DC, Si M-S, **Morris RE**, Reitz BA, Changelian PS: JAK3 inhibition as a new concept for immune suppression. *Current Opinion in Investigational Drugs* 2003, 4 (11):1297-1303.
207. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, Rizzuti BJ, Sawyer PS, Perry BD, Brissette WH, McCurdy SP, Kudlacz EM, Conklyn MJ, Elliott EA, Koslov ER, Fisher MB, Strelevitz TJ, Yoon K, Whipple, DA, Sun J, Munchhof MJ, Doty JL, Casavant JM, Blumenkopf TA, Hines M, Brown MF, Lillie BM, Subramanyam C, Shang-Pao C, Milici AJ, Beckius GE, Moyer JD, Su C, Woodworth TG, Gaweco AS, Beals CR, Littman BH, Fisher DA, Smith JF, Zagouras P, Magna HA, Saltarelli MJ, Johnson KS, Nelms LF, Des Etages SG, Hayes LS, Kawabata TT, Finco-Kent D, Baker DL, Larson M, Si M-S, Paniagua R, Higgins J, Holm B, Reitz B, Zhou Y-J, **Morris RE**, O'Shea JJ, Borie DC: Prevention of organ allograft rejection by a specific Janus Kinase 3 inhibitor. *Science*, 2003; 302:875-878.
208. Stalder M, Birsan T, Hubble RW, Paniagua RT, **Morris RE**: In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primates. *Journal of Heart & Lung Transplantation*. 2003, 22 (12)1343-1352.
209. Stalder M, Birsan T, Holm B, Haririfar M, Scandling J, **Morris RE**: Quantification of immunosuppression by flow cytometry in stable renal transplant recipients. *Therapeutic Drug Monitoring*. 2003, 25 (1) 22-27.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

210. Birsan Tudor, Hausen B, Higgins JP, Hubble RW, Klupp J, Stalder M, Celniker A, Friedrich S, O'Hara RM, **Morris RE**: Treatment with humanized monoclonal antibodies against CD80 and CD86 combined with sirolimus prolongs renal allograft survival in cynomolgus monkeys. *Transplantation*, 2003 75 (12) 2106-2113
211. Dambrin C, Klupp J, Birsan T, Luna J, Suzuki T, Lam T, Stahr P, Hausen B, Christians U, Fitzgerald P, Berry G, **Morris RE**: Sirolimus (rapamycin) monotherapy prevents graft vascular disease in nonhuman primate recipients of orthotopic aortic allografts. *Circulation*. 2003, 107(18):2369-74
212. Freitag DG, Abel MD, Aspeslet LJ, Trepanier DJ, Mayo PR, Halloran PF, Kneteman NT, **Morris RE**, Gregory CR, Foster RT, Yatscoff RW: Development of the novel immunosuppressive agent ISATX247 using a pharmacodynamic approach. *Toxicological Sciences* 2003, 72 :4-4
213. Gregory CR, Kyles AE, Bernsteen L, Wagner GS, Tarantal AF, Christe KL, Brignolo L, Spinner Abigail, Griffey SM, Paniagua RT, Hubble RW, Borie DC, **Morris RE**: Compared with Cyclosporine, ISATX247 Significantly Prolongs Renal-Allograft Survival in a Nonhuman Primate Model. *Transplantation*. 2004, 78(5):681-685
214. Lam TT, Hausen B, Boeke-Purkis K, Paniagua R, Lau M, Hook L, Berry G, Higgins J, Duthaler R, Katopodis A, Robbins R, Reitz B, Borie DC, Schuurman H, **Morris RE**: Hyperacute rejection of hDAF-transgenic pig organ xenografts in cynomolgus monkeys: influence of pre-existing anti-pig antibodies and prevention by the α Gal glycoconjugate GAS914; *Xenotransplantation* 2004: 11: 517-524

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

215. Flores MG, Zhang S, Ha A, Holm B, Reitz BA, **Morris RE**, Borie DC: In vitro evaluation of the effects of candidate immunosuppressive drugs: flow cytometry and quantitative real-time PCR as two independent and correlated read-outs; 2004: Journal of Immunological Methods 2004: 289(1-2) 123-135
216. Klupp J, Van Gelder T, Dambrin C, Regieli JJ, Boeke K, Billingham ME, **Morris RE**: Sustained suppression of peripheral blood immune functions by treatment with mycophenolate mofetil correlates with reduced severity of cardiac allograft rejection. Journal of Heart & Lung Transplantation. 2004: 23(3). 334-351
217. Lam TT, Boeke-Purkis K, Lau M, Paniagua R, Schuurman H-J, **Morris RE**: Anti-pig antibody levels in nonhuman primates of various origin. Xenotransplantation. 2004;11:332-339.
218. Lam TT, Paniagu R, Shivaram G, Schuurman H-J, Borie D, **Morris RE**: Anti-non-Gal porcine endothelial cell antibodies in acute humoral xenograft rejection of hDAF-transgenic porcine hearts in cynomolgus monkeys. Xenotransplantation. 2004, 11, 6, 531-535
219. Murata S, Sundell CL, Lijkwan MA, Balsam LB, Hammainen P, Coleman C, York C, Luchoomun J, Suen K-L, Howard R, Somers PK, **Morris RE**, Robbins RC: Effects of AGI-1096, a novel antioxidant compound with anti-inflammatory and antiproliferative properties, on rodent allograft arteriosclerosis; Transplantation. 2004. 77(10). 1494-1500.
220. Dosanjh A, Ikonen T, **Morris RE**: Respiratory epithelial expression of integrin alphaVbeta6 in chronic progressive allograft rejection; Journal of Heart & Lung Transplantation. 23(4) 2004. 456-460.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

221. Briffa NP, Shorthouse R, Chan J, Silva H, Billingham M, Brazelton T, **Morris RE**: Histological and immunological characteristics of, and the effect of immunosuppressive treatment on, xenograft vasculopathy. *Xenotransplantation*. 11(2) 2004. 149-159
222. **Morris RE**: The future of immunosuppression: A personal view. *Transplantation Proceedings*. 36(2S) 2004. 577-579
223. Burkhart C, Heusser C, **Morris RE**, Raulf F, Weckbecker G, Weitz-Schmidt G, Welzenbach K: Pharmacodynamics in the Development of New Immunosuppressive Drugs. *Ther Drug Monit*. 2004, 26:588-593
224. Birsan T, Dambrin C, Marsh KC, Jacobsen W, Djuric SW, Mollison KW, Christians U, Carter GW, **Morris RE**: Preliminary in vivo pharmacokinetic and pharmacodynamic evaluation of a novel calcineurin-independent inhibitor of NFAT, *Transplant International*. 2004, 17: 145-150
225. Voshol H, Brendlen N, Müller D, Inverardi B, Augustin A, Pally Ch, Wieczorek G, **Morris, RE**, Raul F, van Oostrum J: Evaluation of Biomarker Discovery approaches to Detect Protein Biomarkers of Acute Renal Allograft Rejection, *Journal of Proteome Research*. 2005, 4, 1192 – 1199
226. Birsan T, Dambrin C, Freitag DG, Yatscoff RW, **Morris RE**: The novel calcineurin inhibitor ISATX247: a more potent immunosuppressant than cyclosporine in vitro; *Transplant International*, 2005, 17: 767-771

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

227. Paniagua R, Holm B, Lau M, Kale A, Changelian PS, Larson M, Reitz BA, **Morris RE**, Borie DC: Quantitative analysis of the immunosuppressant CP-690,550 in whole blood by column-switching high-performance liquid chromatography and mass spectrometry detection; *Ther Drug Monit.* 2005; 27(5):608-16.
228. Lam TT, Hausen B, Hook L, Lau M, Higgins J, Christians U, Jacobsen W, Baluom M, Duthaler R, Katopodis A, Chavez G, Cozzi E, Harrison R, Schuurman H-J, Borie D, and **Morris RE**: The effect of soluble complement receptor type 1 on acute humoral xenograft rejection in hDAF-transgenic pig-to-primate life-supporting kidney xenografts, *Xenotransplantation.* 2005, 12, 1, 20-29
229. Stalder M, Tye T, Lam TT, Chan MCY, Berry GJ, Borie DC, **Morris RE**: Improved assessment of graft function by echocardiography in cynomolgus monkey recipients of hDAF-transgenic pig cardiac xenografts, *The Journal of Heart and Lung Transplantation.* 2005. 24, 2, 215-221,
230. Borie DC, Changelian PS, Larson MJ, Si M-S, Paniagua R, Higgins JP, Holm B, Campbell A, Lau M, Zhang S, Flores MG, Rousvoal G, Ball DA, Hawkins J, Kudlacz EM, Brissette WH, Elliott EA, Reitz BA, **Morris RE**: Immunosuppression by the JAK3 Inhibitor CP-690,550 Delays Rejection and Significantly Prolongs Kidney Allograft Survival in Nonhuman Primates: *Transplantation.* 2005; 79: 791-801
231. Chan MCY, Stalder M, Lam TT, Tye T, Borie DC, **Morris RE**: Use of Echocardiography to Assess Function of HDAF-Transgenic Pig Cardiac Xenografts, *Transplantation Proceedings,* 37, 1923-1925, 2005

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

232. Stalder M, Birsan T, Hausen B, Borie DC, **Morris RE**: Immunosuppressive effects of surgery assessed by flow cytometry in nonhuman primates after nephrectomy, *Transplant International*. 2005. 18, 1158-1165
233. Lam TT, Hausen B, Hook L, Lau M, Higgins J, Christians U, Jacobsen W, Baluom M, Duthaler R, Katopodis A, Chavez G, Cozzi E, Harrison R, Schuurman HJ, Borie D, **Morris RE**: The effect of soluble complement receptor type 1 on acute humoral xenograft rejection in hDAF-transgenic pig-to-primate life-supporting kidney xenografts. *Xenotransplantation*. 2005. 12(1):20-9
234. Weckbecker G, Bruns C, Fischer KD, Heusser C, Li J, Metzler B, **Morris RE**, Nuesslein-Hildesheim B, Raulf F, Wieczorek G, Zecri F, Zenke G: Strongly reduced alloreactivity and Long-Term Survival Times of Cardiac Allografts in Vav1- and Vav1/Vav2-Knockout Mice, *Transplant International* 2007 20 (4):353-64
235. Weckbecker G, Bruns C, Fischer KD, Heusser C, Li J, Metzler B, **Morris RE**, Nuesslein-Hildesheim B, Raulf F, Wieczorek G, Zenke G: Strongly reduced alloreactivity and long-term survival times of cardiac allografts in Vav1- and Vav1/Vav2-knockout mice. *Transpl Int*. 2007 Apr;20(4):353-64
236. Zahorsky-Reeves JL, Kearns-Jonker MK, Lam TT, Jackson JR, **Morris RE**, Starnes VA, Cramer DV: The xenoantibody response and immunoglobulin gene expression profile of cynomolgus monkeys transplanted with hDAF-transgenic porcine hearts. *Xenotransplantation*. 2007 Mar;14(2):135-44
237. Chapman JR, Valantine H, Albanell J, Arns WA, Campistol JM, Eisen H, Frigerio M, Lehmkuhl H, Marcen R, **Morris RE**, Nashan B, Pascual J, Pohanka E, Segovia J, Zuckermann A: Proliferation signal inhibitor in transplantation: Questions at the

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

- cutting edge. 2007. Transplantation Proceedings. 39 (10):2937-50
238. **Morris, RE**: Discovery and Development of Immunosuppressants for Transplantation: What are the lessons for specialty medicines? Current Opinion in Investigational Drugs. 2008. 9 (5): 451-454.
239. Chadban S, **Morris RE**, Hirsch H, Bunnapradist S, Arns W, Budde K, Immunosuppression in renal Transplantation; Some aspects for the modern era. Transplant Rev. 2008. July 25.
240. Skvara H, Dawid M, Kleyn CE, Kopp T, Fallahi N, Knight H, Dumortier T, Burkhart C, Grenet O, Wagner J, Hijazi Y, **Morris, RE**, McGeown C, Marbach P, Rordorf C, Griffiths CEM, Stingl G, Jung T: The PKC Inhibitor AEB071, may be a therapeutic option for psoriasis. 2008. J Clin Investigation. 118 (9):3181-3199
241. Wagner J, Zenke G, Baier G, Bigaud M, Evenou J-P, Brinkmann V, Pally C, Wieczorek G, Weckbecker G, Beerli C, Bruns C, Heusser C, Burkhart C, Welzenbach K, Kovarik J, Gruber T, Lutz-Nicoladoni C, Thuille N, Albert R, Cooke N, Sedrani R, van Eis M, Vangrevelinghe E, von Matt P, Marbach P, Dumortier T, Geiser M, Strauss A, Rummel G, Stark W, **Morris RE**, Cottens S: Pharmacological Inhibitor of Protein Kinase C Prevents Early T-Cell Activation and Organ Allograft Rejection. Submitted, 2008
242. Knochenmuss R, Zhang J, Houdiere F, Muller A, Pally C, Wieczorek G, **Morris RE**, Raulf F, Falchetto R. Applications of metabolomics by high resolution mass spectrometry to early diagnosis of acute rejection of renal allograft rejection. Submitted, 2008

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

MONOGRAPHS

1. Transplantation's grim reality demands improvements in immunology. Invited profile in Bioresearch Separations Forum, 3, No. 1, Washington D.C., 1986.
2. **Morris, RE**, Metcalfe, S.: Immunosuppression and induced tolerance: prospective approaches for the control of transplant rejection, 1-47, 1996.
3. **Morris, RE**, "Evolution of Immunology" Discovery of New Immunosuppressants for Transplantation, 2006 Evolution of Immunology, Saito, R(Ed.), Iyaku (Medicine + Drug) Journal, Osaka, Japan

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

BOOK CHAPTERS

1. **Morris RE:** Rapamycin. In New Immunosuppressive Drugs, edited by D. Przepiorka, 951-75, 1994.
2. **Morris RE:** Rapamycin for transplantation. In New Immunosuppressive Modalities and Anti-rejection Approaches in Organ Transplantation, edited by J.W. Kupiec-Weglinski, 43-63, 1994.
3. **Morris RE:** New immunosuppressive drugs. In Heart Surgery 1995, edited by L.C. D'alessandro, Rome, 1995, Casa Editrice Scientifica Internazionale, pp. 221-236.
4. **Morris RE:** New immunosuppressants for transplantation. In Thoracic Transplantation, edited by S.J. Shumway and N.E. Shumway, (eds.), Blackwell Science, Cambridge, MA, 1995, pp 445-451.
5. **Morris RE:** New immunosuppressive drugs. New Developments in Transplantation Medicine, 1:30-31, 1995
6. **Morris RE:** New immunosuppressive drugs: mycophenolate mofetil. New Developments in Transplantation Medicine, 2: 10-12, 1995
7. **Morris RE:** New immunosuppressive drugs. In Handbook of Cardiac Transplantation, edited by R. Emery and L. Miller, Hanley & Belfus, Philadelphia, PA, 1995, pp. 109-117.
8. Hayry P and **Morris RE:** Biological agents and third-generation immunosuppressants. In Atlas Clinical Transplantation, ed. A. Harjula and K. Hockerstedt, 194-99, 1995.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

9. **Morris RE:** New small molecule immunosuppressants for transplantation: Review for essential concepts. In Transplantation Immunology, edited by F. Bach and H. Auchincloss, 199-120, 1995.
10. **Morris RE:** New immunosuppressive drugs. In Trends in Organ Transplantation, edited by B.A.H. Williams and D.M. Sandiford-Guttenbeil, Springer Publishing Company, 1996, pp. 83-94.
11. **Morris RE:** New immunosuppressive drugs. In Transplantation of the Liver, edited by R.W. Bussuttil and G.B. Klintmalm, W.B. Saunders, 1996, pp. 760-786.
12. Suthanthiran M, **Morris RE**, Strom TB: Transplantation Immunobiology. In Campbell's Urology, 7th Edition, edited by Walsh et al., 491-504, 1996.
13. Brazelton TR, Cheung A, **Morris RE:** Immunosuppressants in xenografting. In Xenotransplantation: The Transplantation of Organs and Tissues Between Species. edited by D. Cooper, 1996 pp. 602-633.
14. Alfrey EJ, **Morris RE:** Transplant immunopharmacology. Fundamentals of Surgery, 1997.
15. Fox RI and **Morris RE:** Inhibitors of de novo nucleotide synthesis in the treatment of rheumatoid arthritis. In Novel Therapeutic Agents for the Treatment of Autoimmune Diseases, V. Strand, D.L. Scott, and L.S. Simon, eds., Marcel Dekker, New York, NY, 1997, pp. 257-286.
16. Nair RV, Gregory CR, Huang X, Cao W, **Morris RE:** Prevention of arterial restenosis by rapamycin and mycophenolate mofetil: A new role for novel immunosuppressants in the prevention of post-balloon angioplasty restenosis? In The Role of Immune

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

- Mechanisms in Cardiovascular Disease, edited by H-P Schultheiss & P. Schwimmbeck, 1997, pp 270-281.
17. **Morris RE**: Investigational immunosuppressants: non-biologics. In ASTP Primer on Transplantation, 103-112, 1999.
 18. Gummert JF, Ikonen, T, **Morris RE**: New Immunosuppressive Agents, in *Transplantation Immunobiology*, edited by R. J. Duquesnoy. 2000.
 19. Klupp J, and **Morris RE**. Unapproved Non-Biologic Immunosuppressants, in Pediatric Solid Organ Transplantation, Eds., AH Tejani, WE Harmon and RN Fine. Copenhagen: Munksgaard, 121-134, 2000.
 20. Briffa NP, Gregory CR, **Morris RE**: Immunosuppressive Drugs for the Prevention and Treatment of Transplant Coronary Artery Vasculopathy. In Transplant Associated Coronary Artery Vasculopathy, edited by M.L. Rose, Georgetown, Texas: R. G. Landes Co., 2001.
 21. Gummert JF, Ikonen TS, **Morris RE**: Newer Immunosuppressants in Transplant Rejection. in Cardiac Allograft Rejection. M. Ballester, I. Carrio, G.W. Dec, J. Narula, editors, Springer-Verlag, 2001.
 22. Klupp J, **Morris RE**: Unapproved nonbiologic immunosuppressants. In Primer on Transplantation, 119-132, 2001.
 23. Klupp J, **Morris RE**: Unapproved nonbiologic immunosuppressants. In Heart and Lung Transplantation, edited by Baumgartner WA, Kasper E, Reitz B and Theodore J, W.B. Saunders, 2002, pp. 567-577.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

PUBLISHED ABSTRACTS

1. **Morris RE**, Thomas, P.T. and Hong, R.: Detection of cell surface antigens by the cellular enzyme-linked immunosorbent assay (CELISA) *Human Immunology*, 3:377, 1981.
2. Shorthouse R and **Morris RE**: Use of enzyme assays to assess *in vitro* lymphocyte activation. *Fed. Proc.*, 46:634, 1986.
3. Cheng PJ and **Morris RE**: A new rapid, high capacity chromatographic technique for the purification of IgG₁ monoclonal antibodies directly from mouse ascites. *Fed. Proc.*, 46:733, 1986.
4. **Morris RE** and Shorthouse R: "Turbo ELISA" or how to get the most from alkaline phosphatase conjugates. *Fed. Proc.*, 46:733, 1986.
5. DeValeria P and **Morris RE**: Re-transplanted tissue from long-term allografts is highly immunogenic. *Fed. Proc.*, 45:267, 1986.
6. Hoyt G, DeValeria P, Whitehead J and **Morris RE**: Concanavalin A and its succinylated derivative are nontoxic immunosuppressants of graft rejection. *Fed. Proc.*, 45:500, 1986.
7. Skogen B, DeValeria P, Clark W, Cheng P, Kim J, and **Morris RE**: Anticardiac myosin monoclonal antibody demarcates cardiac rejection. *Fed. Proc.*, 45:501, 1986.
8. Keller J, DeValeria P and **Morris RE**: 1,4-BIS<(2-Aminoethyl) Amino>-5, 8-Dihydroxy-9, 10-Anthracendione (AEAD) and Mitoxantrone (MXN) are ineffective immunosuppressants for cardiac transplantation. *FASEB J.*, 2:1847, 1988.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

9. Shorthouse R and **Morris RE**: Development of a radiometric host vs. graft rejection (HVGR) popliteal lymph node (PLN) assay to evaluate immunosuppressive (IS) drugs. FASEB, 2:1846, 1988.
10. Gudas V and **Morris RE**: FK-506 does not prolong rat cardiac xenograft survival. FASEB J., 2:1847, 1988.
11. Carmichael PG and **Morris RE**: Alteration of in vivo allogeneic functions by ultraviolet B (UVB). FASEB J., 2:1847, 1988.
12. **Morris RE**, R Shorthouse R, Hoyt G: Initial studies on oral FK-506 in cardiac allograft recipients: dose response, effect of splenectomy, and synergism with cyclosporine (CsA). FASEB J., 2:1847, 1988.
13. Yuh DD, Zurcher B, Rulifson E and **Morris RE**: Efficacy of Didemnin B therapy in prolonging cardiac allograft survival in mice and rats. FASEB J., 2:1846, 1988.
14. Meiser BM, Reichart B, **Morris RE**: FK506(FK) and rapamycin (RPM), two new immunosuppressive macrolides have much more efficacy and less side effects than cyclosporine (CsA) in experimental heart transplantation. The Thoracic and Cardiovascular Surgeon, 38(Supplement 1):90, 1990.
15. Meiser BM, Billingham ME, **Morris RE**: The effect of cyclosporine and two new immunosuppressive macrolides FK506 and rapamycin, on heart graft rejection and graft coronary atherosclerosis. J. Heart Transplant., 9:55, 1990.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

16. **Morris RE**, Hoyt EG, Wang J: RS-61443 (RS) is a novel and specific inhibitor of T and B cell purine synthesis that induces transplant tolerance reverses acute rejection and prolongs xenograft survival. *J. Heart Transplant.*, 9:62, 1990.
17. **Morris RE**, Wang J, Wu J, Shorthouse R, and Meiser B: Induction of graft tolerance by brief treatment with rapamycin (RPM): a new, far more potent and effective immunosuppressant than cyclosporine A. *J. Heart Transplant.*, 9:62, 1990.
18. **Morris RE** and Yuh DD: 15-Deoxyspergualin: an immunopharmacologic and mechanistic analysis of an effective immunosuppressant. *J. Heart Transpl.*, 55:73, 1990.
19. **Morris RE**, Wang J, Zheng B: A new paradigm for immunoregulation: prolongation of allograft survival by potent T-cell mitogen. *J. Heart Transpl.*, 55:73, 1990.
20. Figari I, **Morris RE** and Palladino M: Regulation of immune functions in vivo by transforming growth factor-beta. *FASEB J.*, 4:A1866, 1990.
21. **Morris RE**, Wang J, Wu J, Shorthouse R and Meiser B: Induction of graft tolerance by brief treatment with rapamycin (RPM): a new, far more potent and effective immunosuppressant than cyclosporine (CsA). *FASEB J.*, 4:A2267, 1990.
22. Yuh DD and **Morris RE**: 15-Deoxyspergualin: an immunopharmacologic and mechanistic analysis of an effective immunosuppressant. *FASEB J.*, 4:A2267, 1990.
23. Wang J, **Morris RE**, Allison AC and Eugui E: RS-61443 (RS) is a novel and specific inhibitor of T and B cell purine synthesis that induces transplant tolerance, reverses acute rejection, and prolongs xenograft survival. *FASEB J.*, 4:A2268, 1990.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

24. **Morris RE**, Rodriguez M, Murphy M, Billingham M, and Wang J: Treatment of rat heart allograft recipients with RS-61443: prevention of graft coronary disease and effective combined treatment with FK506, rapamycin and cyclosporine. *J. Heart and Lung Transplant*, 10:182, 1991.
25. **Morris RE**, Wang J, Gregory C, Jiang B: Initial studies of the efficacy and safety of rapamycin administered to cynomolgus monkey recipients of heart allografts. *J. Heart and Lung Transplant*, 10:182, 1991.
26. Wang J, **Morris RE**, Blum J, Flavin T, Almquist S, Chun N, Allison A, and Eugui E: Study of the immunosuppressive, pharmacokinetic, and pharmacodynamic effects of RS-61443 monotherapy in cynomolgus monkey recipients of heart allografts. *J. Heart and Lung Transplant*, 10:175, 1991.
27. Murphy MP, **Morris RE**: The new antimetabolite immunosuppressant Brequinar sodium (Dup 785) selectively, effectively, and potently suppresses and reverses cardiac allograft rejection. *J. Heart and Lung Transplant*, 11:223, 1992.
28. Wang J, **Morris RE**: Heterotopic transplantation of beating atrial tissue allografts (ATA) beneath the renal capsule is a new and simple technique for the study of rejection and its treatment. *J. Heart and Lung Transplant*, 11:234, 1992.
29. Zheng B, Beschoner WE, Shorthouse R, and **Morris RE**: Mechanisms of tolerance induction by rapamycin: demonstration by immunohistochemistry of unique alterations caused by rapamycin treatment. *J. Heart and Lung Transplant*, 11:198, 1992.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

30. Nakakura E, Jardieu P, Zheng B, **Morris RE**: An anti-adhesion molecule (FLA-1, CD11a) monoclonal antibody suppresses ongoing rejection and prolongs heart allograft survival indefinitely without lymphocyte depletion. *J. Heart and Lung Transplant*, 11:223, 1992.
31. Gregory C, **Morris RE**, Pratt R, Billingham M, Shorthouse R: The use of new antiproliferative immunosuppressants is a novel and highly effective strategy for the prevention of vascular occlusive disease. *J. Heart and Lung Transplant*, 11:197, 1992.
32. Gregory CR, **Morris RE**, Pratt M, Billingham M, Shorthouse R: Use of antiproliferative agents for the treatment of occlusive vascular disease. *FASEB J.*, 6:A940, 1992.
33. **Morris RE**: New immunosuppressive compounds in transplantation. *Fesenius J. Anal. Chem.*, 343:32, 1992.
34. Mohacsi P, Zheng B, Shorthouse R, **Morris RE**: A paradox of immunosuppression by rapamycin: lymphocytes from rats treated with rapamycin are hypo-responsive to alloantigens in vivo but hyper-responsive to alloantigens in the mixed lymphocyte reaction. *J. Heart and Lung Transplant*, 12:S73, 1993.
35. **Morris RE**, Gregory C, Huie P, Shorthouse R, Ohsumi S, Billingham M, Wang J: Rapamycin reverses severe heart allograft rejection in rats and nonhuman primates: mechanisms of rapamycin's actions at the cellular and molecular levels. *J. Heart and Lung Transplant*, 12:S74, 1993.
36. Gregory CR, Wang J, Cao W, Shorthouse R, Huang X, Rowan R, Billingham M, **Morris RE**: Leflunomide is a new immunosuppressant that effectively reduces

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

- arterial intimal thickening produced by alloimmune injury. *J. Heart and Lung Transplant.* 13(1):S 68, 1994.
37. Cao W, Chao AC, **Morris RE**: Leflunomide, A New Immunosuppressant, Inhibits Tyrosine Kinase, Calcium Signaling and DNA Synthesis in Vascular Smooth Muscle Cells. *FASEB Journal*, 8:A486, 1994.
38. Cao W, Kao P, Xu J, Chao A, Gardner P, and **Morris RE**: Studies of the immunosuppressive actions of A1726, the active metabolite of leflunomide (LFM): description of a novel mechanism of action for the anti-proliferative effects on lymphocytes. *The Immunologist*, 1995.
39. Nair R, Cao W, and **Morris RE**: Molecular mechanism of suppression of arterial intimal thickening by leflunomide (LFM): demonstration of direct antiproliferative effect on murine vascular smooth muscle cells (M-VSMC) in vitro and antagonism of action by uridine. *J. Heart and Lung Transplant.*, 14(1):S54, 1995.
40. Huang X, Reichenspurner H, Shorthouse R, Cao W, Berry G, and **Morris RE**: Heterotopic tracheal allograft transplantation: a new model to study the cellular and molecular events causing obliterative airway disease (OAD) in rats. *J. Heart and Lung Transplant.*, 14(1):S49, 1995.
41. **Morris RE**, Huang X, Shorthouse R, Reichenspurner H, Adams B, and Berry G: Use of cyclosporine (CsA), mycophenolic acid (MPA), rapamycin (RPM), leflunomide (LFM) or deoxyspergualin for prevention and treatment of obliterative airway disease (OAD) in new animal models. *J. Heart and Lung Transplant.*, 14(1):S65, 1995.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

42. Yuh DD, **Morris RE**, Hoyt G, Gutierrez J, and Robbins R: Leflunomide effectively prolongs lung allo- and xenograft survival. *J. Heart and Lung Transplant.*, 14(1):S73, 1995.
43. Silva HT, Shorthouse R, Cao W, **Morris RE**: Studies of the pharmacodynamics of leflunomide's (LFM) active metabolite, A771726 using whole blood assay (WBA), 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY. The 9th International Congress of Immunology 1995. 855.
44. Gregory CR, Lirtzman RL, Griffey SM, Yeh L, Patz JD, and **Morris RE**: Combination leflunomide and cyclosporine immunosuppression prevents MLR mismatched allograft rejection in mongrel dogs. *J. Heart and Lung Transplant.*, 14(1):S51, 1995.
45. Gregory CR, Patz JD, Berryman ER, Cooke JP, Shorthouse R, and **Morris RE**: Nitric oxide induced by the administration of L-arginine does not inhibit arterial neointimal formation following alloimmune injury. *J. Heart and Lung Transplant.*, 14(1):S45, 1995.
46. Cao W, Kao P, Xu J, Chao A, Gardner P, **Morris RE**: Molecular mechanism of lymphocyte specific anti-proliferative action of leflunomide, a novel and effective immunosuppressant. *FASEB J*, 9:A1370, 1995.
47. **Morris RE**, Huang X, Shorthouse R, Reichenspurner H, Adams B, Berry G: Tracheal allograft transplantation: A model of obliterative airway disease (OAD) and its treatment with new immunosuppressive drugs. Abstract book, 9th International Congress of Immunology, 856, 1995.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

48. Reichenspurner R, Shorthouse R, Cao W, Berry G, **Morris RE**: The cellular and molecular events causing obliterative airway disease (OAD) after heterotopic tracheal allograft transplantation in rats. Abstract book, 9th International Congress of Immunology, 648, 1995.
49. Silva HT, Shorthouse R, Cao W, **Morris RE**: Studies of the pharmacodynamics of leflunomide's (LFM) active metabolite, A771726, using whole blood assay (WBA). Abstract book, 9th International Congress of Immunology, 855, 1995.
50. Cao W, Kao P, Chao A, **Morris RE**: Molecular mechanism of lymphocyte specific antiproliferative action of leflunomide, a novel and effective immunosuppressant. Abstract book, 9th International Congress of Immunology, 855, 1995.
51. **Morris RE**, Huang X, Shorthouse R, Reichenspurner H, Adams B, Berry G: Use of cyclosporine (CsA), mycophenolic acid (MPA), rapamycin (RPM), leflunomide (LFM) or deoxyspergualin (DSG) for prevention and treatment of obliterative airway disease (OAD) in new animal models, Journal of Heart & Lung Transplantation. 14(1 PART 2).1995. S65.
52. Reichenspurner H, Soni V, Brazelton T, Shorthouse R, Boname, J, Adams B, Nitschke M, Girgis R, Reitz BA, Mocarski E, Sandford G, Berry G, **Morris RE**: Enhancement of obliterative airway disease (OAD) rat tracheal allografts infected with genetically engineered cytomegalovirus (CMV). The Journal of Heart and Lung Transplantation, 15(1) Part 2: S45, 1996.
53. Silva HT, Cao W, Shorthouse R, **Morris RE**: Inhibition of pyrimidine biosynthesis in lymphocytes is a mechanism of immunosuppressive action *in vivo* of the novel immunosuppressant, leflunomide (LFM): Uridine reverses the antiproliferative effects

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

- of LFM after *in vivo* treatment. The Journal of Heart and Lung Transplantation, 15(1) Part 2: S63, 1996.
54. Reichenspurner H, Soni V, Adams B, Brazelton T, Shorthouse R, Reitz BA, Berry G, **Morris RE**: Pathogenesis and treatment of obliterative airway disease (OAD) after xenogeneic tracheal transplantation in rodents. The Journal of Heart and Lung Transplantation, 15(1) Part 2: S92, January 1996.
55. Nair RV, **Morris RE**: Cellular and molecular mechanisms for inhibition by rapamycin (RPM) of experimental allograft obliterative airway disease (OAD): Inhibition of growth-factor stimulated human adult lung fibroblast (HALFB) proliferation *in vivo* by RPM. Journal Heart Lung Transplant 15(1) Part 2: S98, January 1996.
56. Silva HT, Jr, Huang X, Cheung A, Shorthouse R, Billingham M, **Morris RE**: Optimization of preclinical drug development: correlation among dosing schedule, pharmacokinetics (PK), pharmacodynamics (PD) and degree of histologic rejection in leflunomide (LFM)-treated heart transplanted rats. J Amer Soc Neph 7(9):3244, September 1996.
57. Silva HT, Jr, Cao W, Shorthouse R, Loffler M, **Morris RE**: Evidence that *in vitro* and *in vivo* antiproliferative effects of leflunomide (LFM) are mediated by inhibition of *de novo* pyrimidine biosynthesis: *in vivo* inhibition of dihydroorotate dehydrogenase (DHOdehase). J Amer Soc Neph 7(9): 1895, September 1996.
58. Braun-Dullaeus RC, von der Leyen HE, Mann MJ, Zhang L, **Morris RE**, Dzau VJ: Loss of p27^{Kip1} and induction of Cdk1 in the rat carotid artery following balloon catheter injury: *in vivo* and *in vitro* influence of rapamycin. FASEB J 11: A153, 1997.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

59. Silva HT, Bryce T, Wade A, **Morris RE**: Single- and multiple-dose pharmacokinetics (PK) of two leflunomide analogues, the malononitralimides (MNAS) HMR1279 and HMR1715. *Therapeutic Drug Monitoring*, 19: 5, 1997.
60. Silva HT, Slauson S, Shorthouse R, Cao W, Loffler M, **Morris RE**: Molecular mechanism of the immunosuppressive effect of leflunomide in vivo: inhibition of dihydroorotate dehydrogenase (DHODH). *Therapeutic Drug Monitoring*, 19: 5, 1997.
61. Silva HT, Sherwood S, Bryce T, Wade A, Wang Y, Shorthouse R, Billingham M, **Morris RE**: Relevance of combined pharmacokinetic/pharmacodynamic (PK/PD) Studies to optimize administration and efficacy of two leflunomide analogues, the malononitralimides (MNAS) HMR 1279 and HMR1715. *Therapeutic Drug Monitoring*, 19:5, 1997
62. Fahmi T, Berry GJ, **Morris RE**, and Rosen GD: Rapamycin inhibits development of obliterative airway disease in a murine heterotopic airway transplant model. *Transplantation*, 63, 533-537, No. 4, February 27, 1997.
63. Gregory CR, Galili U, Griffey SM, Hancock WW, Valverde C, Berryman ER and **Morris RE**: Squirrel monkeys hyperacutely reject porcine musculocutaneous flaps despite a lack of naturally occurring xenoantibodies. *Veterinary Surgery* 1997, 25(5):415, #30.
64. Gregory CR, Silva H, Patz JD and **Morris RE**: Comparative effects of malononitralimide analogs of leflunomide on whole blood lymphocyte stimulation in human beings, rhesus macaques, cats, dogs and rats. *Veterinary Surgery* 1997, 26(5):415, #31.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

65. Hausen B, Ikonen T, Briffa N, Berry GJ, Christians U, Robbins RC, Sherwood S, Schuler W, and **Morris RE**: Successful suppression of lung allograft rejection in non-human primates by combined treatment using the new Rapamycin derivative, SDZ RAD, plus microemulsion cyclosporine. *The Journal of Heart and Lung Transplantation*, 17:1, 43, 1998.
66. Ikonen T, Polak JM, Bishop AE, Uusitalo M, Salminen US, Taskinen E, and **Morris RE**: Inducible nitric oxide synthase (iNOS) and nitrotyrosine expression is suppressed in heterotopic pig lung and bronchus implants before the development of airway obliteration. *The Journal of Heart and Lung Transplantation*, 17:1, 46, 1998.
67. Adams BF, Brazelton T, Lange E, Huang X, and **Morris RE**: Airway epithelial cells prevent obliterative airway disease (AD) in heterotopically transplanted rat tracheal grafts. *The Journal of Heart and Lung Transplantation*, 17:1, 47, 1998.
68. Brazelton TR, Shorthouse R, Gregory CR, Huang X, and **Morris RE**: Recipient mesenchymal cells infiltrate and remodel medial and adventitial tissue in the rat femoral artery allograft model of chronic vascular rejection. *The Journal of Heart and Lung Transplantation*, 17:1, 61, 1998.
69. Hausen B, Boeke K, Berry GJ, Christians U, **Morris RE**. Successful treatment of acute, ongoing rat lung allograft rejection with SDZ RAD, a new rapamycin analog. *American Review of Respiratory Diseases*, 157(3): 331, 1998.
70. Hausen B, Berry GJ, Dagum P, Ikonen T, Briffa N, Robbins RC, and **Morris RE**: The histology of subcutaneously implanted donor bronchial rings correlates with rejection scores of lung allografts in a primate lung transplant model. *The Journal of Heart and Lung Transplantation*, 17:1, 67, 1998.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

71. Silva HT, Slauson SD, Shorthouse R, Löffler M, and **Morris RE**: Inhibition of dihydroorotate dehydrogenase (DHODH) is the molecular mechanism of immunosuppression by malononitrilamides (MNA's) in vivo. *The Journal of Heart and Lung Transplantation*, 17:1, 74, 1998.
72. Hausen B, Boeke K, Gerry GJ, Christians U, and **Morris RE**: SDZ RAD, a new Rapamycin analogue, effectively suppresses rat lung allograft rejection. *The Journal of Heart and Lung Transplantation* 17:1, 76, 1998.
73. Ikonen T, Briffa N, Brazelton T, Shorthouse R, Berry G, and **Morris RE**: Prevention of obliterative airway disease (OAH) in heterotopic rat tracheal allografts without immunosuppression: Anastomosis of recipient trachea to donor trachea enables re-epithelialization of allografts by recipient epithelium. *The Journal of Heart and Lung Transplantation*, 17:1, 77, 1998.
74. Morikawa M, Sherwood SW, Shorthouse RA, Suto MJ, Manning AM, and **Morris RE**: The first T-cell specific dual inhibitor of NF- κ B and AP-1 prevents allograft rejection in mice by an antiproliferative effect mediated by inhibition of IL-2 production. *The Journal of Heart and Lung Transplantation*, 17:1, 79, 1998.
75. Silva HT, Sherwood S, Bryce T, Wade A, Wang X, Cheung A, Wang Y, Shorthouse R, Slauson S, Billingham M, and **Morris RE**: Pharmacokinetic/pharmacodynamic (PK/PD) strategy to optimize administration, efficacy and safety of the malononitrilamides (MNA) A77 1726, HMR 1279 and HMR1715. *The Journal of Heart and Lung Transplantation*, 17:1, 80, 1998.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

76. Vriens PW, Pollard JD, Hoyt G, Scheringa M, Bouwman E, **Morris RE**, and Robbins RC: Presence of antibodies is required for the induction of accommodation in xenotransplantation. *The Journal of Heart and Lung Transplantation*, 17:1, 88, 1998.
77. Ikonen T, Briffa N, Gummert J, Honda Y, Perlroth J, Hayase M, Robbins RC, Barlow C, Billingham ME, Hausen B, Yock PG, and **Morris RE**: Progressive graft vascular disease (GVD) by serial intravascular ultrasound (IVUS) in a novel model of combined aortic auto- and allograft transplantation in nonhuman primates. *The Journal of Heart and Lung Transplantation*, 17:1, 100, 1998.
78. Wang Y, Silva H, Billingham M, Shorthouse R, Thronset B, and **Morris RE**: Malononitrilamides (MNA) abrogate the heart graft accelerated rejection in presensitized rats. *The Journal of Heart and Lung Transplantation*, 17:1, 108, 1998.
79. Slauson SD, Silva HT, Wang Y, Gummert J, Barten M, Billingham M, and **Morris RE**: Coadministration of HMR1279, a malononitrilamide (MNA), with cyclosporine prevents acute rat heart allograft rejection: Combined study of pharmacodynamics (PD), pharmacokinetics (PK) and drug efficacy. *The Journal of Heart and Lung Transplantation*, 17:1, 109, 1998.
80. Morikawa M, Sherwood SW, Suto MJ, Manning AM, and **Morris RE**: CD28 costimulation of proliferation in murine splenic T cells is sensitive to inhibition by SP100030, a novel T cell-specific dual inhibitor of NF- κ B and AP-1. *Transplantation*, 65:12, S28, 1998.
81. Silva HT, Slauson S, Shorthouse R, Löffler, and **Morris RE**: Inhibition of dihydroorotate dehydrogenase (DHODH) is the molecular mechanism of

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

- immunosuppression by the malononitrilamides (MNAs) in vivo. *Transplantation*, 65:12, S28, 1998.
82. Brazelton TR, Shorthouse R, Gregory CR, Huang X, and **Morris RE**: Recipient mesenchymal cells infiltrate and remodel medial and adventitial tissue in the rat femoral artery allograft model of chronic vascular rejection. *Transplantation*, 65:12, S37, 1998.
83. Ikonen T, Briffa N, Brazelton T, Shorthouse R, Berry G, and **Morris RE**: Prevention of obliterative airway disease (OAD) without immunosuppression in heterotopic rat tracheal allografts: Anastomosis of recipient trachea to donor trachea enables re-epithelialization of allografts by recipient epithelium. *Transplantation*, 65:12, S37, 1998.
84. Dosanjh A, Wan B, and **Morris RE**: Lung epithelium-derived IL-10 stimulates lung fibroblast proliferation in vitro: Implications for the pathogenesis of obliterative bronchiolitis after lung transplantation. *Transplantation*, 65:12, S38, 1998.
85. Silva HT, Slauson S, Sherwood S, Bryce T, Wade A, Wang X, Cheung A, Wang Y, Shorthouse R, Billingham M, and **Morris RE**: Monitoring of pharmacodynamics (PD), but not pharmacokinetics (PK), differentiates the relative immunosuppressive potencies of leflunomide and its malononitrilamide (MNA) analogs. *Transplantation*, 65:12, S42, 1998.
86. Hausen B, Boeke K, Berry GJ, Christians U, Segarra I, Benet LZ, and **Morris RE**: Coadministration of neural and the novel rapamycin analog, SDZ RAD, to lung allograft recipients: Potentiation of immunosuppressive efficacy and reduction of toxicity by staggered vs. simultaneous treatment. *Transplantation*, 65:12: S132, 1998.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

87. Hausen B, Boeke K, Berry GJ, Christians U, Gummert J, Benet LZ, and **Morris RE**: Coadministration of microemulsion, cyclosporine and the novel leflunomide malononitrilamide analog, HR1279, more effectively suppresses rat lung allograft rejection than microemulsion cyclosporine plus leflunomide. *Transplantation* 65:12, S133, 1998.
88. Slauson S, Silva H, Sherwood S, and **Morris RE**: Flow cytometric (FCM) analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide (MNA) analogs in a novel whole blood assay. *Transplantation*, 65:12, S134, 1998.
89. Doyle R, Wong R, Newmark R, Dingemans A, Lin T, Dou, L, Brazelton T, Altinger J, Poirier C, and **Morris RE**: Safety and tolerability of two different single doses of SDZ RAD in lung transplant recipients. *Transplantation*, 65:12, S158, 1998.
90. Hausen B, Ikonen T, Berry GJ, Christians U, Robbins RC, Hook L, Benet LZ, Schuler W, and **Morris RE**: Coadministered neoral and the new rapamycin derivative, SDZ RAD, for nonhuman primate lung transplantation: Systematic pharmacokinetic-based trials to maximize efficacy and tolerability. *Transplantation*, 65:12, S172, 1998.
91. Gummert J, Ikonen T, Briffa N, Honda Y, Perloth J, Hayase M, Hausen B, Billingham ME, Barlow C, Robbins RC, Yock PG, and **Morris RE**: Graft vascular disease (GVD) in non-human primates: Quantitation of changes in arterial auto- and allografts by intravascular ultrasound (IVUS). *Transplantation*, 65:12, S183, 1998.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

92. Dingemans SA, Wong R, Dou L, Smith T, Newmark R, Doyle R, Brazelton T, Altinger J, Poirier C, and **Morris RE**: First pharmacokinetic study with SDZ RAD in stable lung transplant recipients. *Transplantation*, 65:12, S188, 1998.
93. Gummert JF, Barten MJ, Wang Y, Billingham ME, and **Morris RE**: Therapeutic monitoring of mycophenolic acid (MPA): Assays of immune function in peripheral blood predict efficacy for inhibition of histologic graft rejection. *The Journal of Heart and Lung Transplantation*, 18:1, 53, 1999.
94. Brazelton TR, Doyle RL, Poirier C, Wong RL, Newmark RD, Bush C, Altinger J, Hausen B, Reitz BA, Theodore J, and **Morris RE**: Analysis of risk factors for chronic lung rejection from a twelve-center, multinational database. *The Journal of Heart and Lung Transplantation*, 18:1, 59, 1999.
95. Brazelton TR, Doyle RL, Wong RL, Newmark RD, Bush C, Theodore J, and **Morris RE**: Heterogeneity and reversal of bronchiolitis obliterans syndrome. *The Journal of Heart and Lung Transplantation*, 18:1, 59, 1999.
96. Ikonen TS, Shorthouse RS, Berry GJ, and **Morris RE**: Epithelial re-growth prevents luminal occlusion in orthotopic tracheal allografts despite acute rejection and proliferation of α -actin positive cells. *The Journal of Heart and Lung Transplantation*, 18:1, 60, 1999.
97. Briffa NP, Shorthouse R, Chang J, Brazelton T, and **Morris RE**: Xenogeneic antibodies are *not* necessary for chronic rejection of vascularised xenografts. *The Journal of Heart and Lung Transplantation*, 18:1, 1999.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

98. Ikonen TS, Gummert JF, Honda Y, Hayase M, Christians U, Serkova N, Hausen B, Yock PG, and **Morris RE**: Sirolimus (rapamycin) blood levels correlate with prevention of graft vascular disease (BVD) in monkey aortic transplants as monitored by intravascular ultrasound. *The Journal of Heart and Lung Transplantation*, 18:1, 72, 1999.
99. Ikonen TS, Adams B, Lange E, Berry GJ, and **Morris RE**: A novel approach to test immunosuppressive drugs in heterotopically transplanted lung fragments in rats. *The Journal of Heart and Lung Transplantation*, 18:1, 73, 1999.
100. Hausen B, Gummert J, Berry GJ, Christians U, Hook L, Ikonen T, Legay F, and **Morris RE**: Basiliximab (áIL2R Mab) induction therapy combined with subtherapeutic doses of neural and SDZ RAD successfully prevents allograft rejection in a nonhuman primate lung transplant model. *The Journal of Heart and Lung Transplantation*, 18:1, 73, 1999.
101. Hausen B, Boeke K, Berry GJ, and **Morris RE**: Inhibition of thromboxane A2 and platelet adhesion with salicylic acid effectively ameliorates reperfusion injury following acute double lung transplantation in the rat. *The Journal of Heart and Lung Transplantation*, 18:1, 79, 1999.
102. Wan B, Ikonen T, **Morris RE**, and Dosanjh AK: IL-6 and IFN- γ expression parallels recovery of the epithelium in a heterotopic rat model of allograft rejection. *The Journal of Heart and Lung Transplantation*, 18:1, 90, 1999.
103. Wan B, Ikonen T, **Morris RE**, and Dosanjh A: Loss of airway goblet cells is associated with respiratory epithelial injury in a rat model of allograft rejection. *The Journal of Heart and Lung Transplantation*, 18:1, 90, 1999.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

104. Kyles, AE, Gregory CR, Craigmill AL and **Morris RE**: Comparison of the anti-proliferative effects of immunosuppressive drugs in cats. *Veterinary Surgery* 1999, 28:397.
105. Barten MJ, van Gelder T, Gummert JF, Boeke K, Billingham ME, and **Morris RE**: Pharmacodynamics (PD) of mycophenolate mofetil (MMF) after heart transplantation identify new mechanism of action and correlate with severity of rejection. *Transplantation*, 67:7, S57, 1999.
106. Barten MJ, Gummert JF, van Gelder T, Shorthouse R, and **Morris RE**: Potencies of immunosuppressive drugs for inhibition of signal 1- and signal 2-induced expression of lymphocyte cell surface activation antigens using whole blood assays. *Transplantation*, 67:7, S57, 1999.
107. Gummert JF, Barten MJ, Wang Y, Billingham ME, and **Morris RE**: Graft rejection in mycophenolic acid (MPA) treated heart transplant recipients is predicted by changes in lymphocyte function over time (pharmacodynamics). *Transplantation*, 67:7, S61, 1999.
108. Gummert JF, Barten MJ, Boeke K, Leon EJ, Decker CJ, Nimmegern E, Billingham ME, and **Morris RE**: The IMPDH inhibitor VX-497 is the first rationally synthesized immunosuppressant to prolong allograft survival. *Transplantation*, 67:7, S62, 1999.
109. Ikonen TS, Gummert JF, Hayase M, Honda Y, Kobayashi Y, Christians U, Hausen BA, Berry GJ, Yock PG, and **Morris RE**: Chronic rejection in non-human primates: Sirolimus (rapamycin), but not cyclosporine, prevents graft vascular disease (GVD) in aortic allografts after acute rejection. *Transplantation*, 67:7, S252, 1999.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

110. Doyle RL, **Morris RE**, Hertz MI, Dunitz JM, Loyd JE, Stecenko AA, Tudor D, Smith HT, Wong RL, Chappell K, and Kovarik JM: Pharmacokinetics of RAD001 (RAD) in stable lung transplant patients with and without cystic fibrosis (CF). *The Journal of Heart and Lung Transplantation*, 19:1, 82, 2000.
111. Hausen B, Klupp J, Hook LE, Christians U, Baumgartner RE, Friedrich S, Celnicker A, **Morris RE**: Coadministration of either microemulsion cyclosporine or steroids with humanized monoclonal antibodies against the B7-1 and B7-2 epitopes successfully prolong allograft survival after life-supporting renal transplantation in cynomolgus monkeys. *Transplantation*, 69:8, S123, 2000.
112. Klupp J, van Gelder T, Regieli J, Shorthouse R, Kavanau K, and **Morris RE**: Development of a novel pharmacodynamic assay in non-human primates. *Transplantation* 69:8, S125, 2000.
113. Doyle RL, Hertz MI, Dunitz JM, Loyd JE, Stecenko AA, Wong RL, Chappell K, Brazelton T, Kovarik JM, **Morris RE**: Safety and pharmacokinetics of two single doses of RAD001 (RAD) in stable lung and heart/lung transplant recipients with and without cystic fibrosis (CF). *Transplantation*, 69:8, S142, 2000.
114. Kyles AE, Gregory CR, Griffey S, Jackson J, Bernsteen L and **Morris RE**: Leflunomide analog, HMR715, plus cyclosporine reduces renal allograft rejection in mismatched mongrel dogs. *The Tenth Annual American College of Veterinary Surgeons Symposium*, September 21-24, 2000, Arlington, VA. *Veterinary Surgery* 29:467.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

115. Kyles AE, Gregory CR, Griffey SM, and **Morris RE**: Immunosuppression with the new leflunomide (LFM) analog, HMR1715 plus cyclosporine (CsA) reduced clinical and histologic evidence of renal allograft rejection in MLR mismatched dogs. *Transplantation*, 69:8, S190, 2000.
116. van Gelder T, Klupp J, Barten MJ, Christians U, and **Morris RE**: Coadministration of tacrolimus and mycophenolate mofetil does not increase mycophenolic acid (MPA) exposure, but coadministration of cyclosporine inhibits the enterohepatic recirculation of MPA, thereby decreasing its exposure. *Transplantation*, 69:8, S192, 2000.
117. Serkova NJ, Jacobsen W, Litt L, Hausen B, **Morris RE**, Benet LZ, Leibfritz D, and Christians U: SDZ-RAD prevents cyclosporine-induced inhibition of brain energy metabolism: Comparison with rapamycin. *Transplantation*, 69:8, S195, 2000.
118. Hausen B, Boeke K, Berry GJ, Acklin S, and **Morris RE**: Viral serine proteinase inhibitor (SERP-1) effectively decreases the incidence of graft vasculopathy in heterotopic heart allografts. *Transplantation*, 69:8, S344, 2000.
119. Van Gelder T, Klupp J, Kavanau K, and **Morris RE**: Novel mechanisms of action of mycophenolic acid (MPA) Inhibition of expression of CD28 and CD154 costimulatory molecules and induction of apoptosis in vivo in humans after treatment with mycophenolate mofetil (MMF). *Transplantation*, 69:8, S393, 2000.
120. Stalder M, Tye T, Chan M, Dambrin C, Pelletier M, Robbins R, Reitz B, Lam T and **Morris RE**: Assessment of graft function by echocardiography in cynomolgus monkey recipients of hDAF-transgenic pig cardiac xenografts. *Xenotransplantation*, 8: supplement 1, 73, August 2001.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

121. Lam T, Hausen B, Hook L, Squires E, Dambrin C, Pelletier M, Robbins R, Reitz B, Cozzi E and **Morris RE**: Cyclophosphamide induced anemia in cynomolgus monkey recipients of hDAF-transgenic pig cardiac and renal xenografts. *Xenotransplantation*, 8: supplement 1, 76. August 2001
122. Lam T, Hausen B, Higgins J, Berry G, Schuurman H, Duthaler R, Katopodis A, Robbins R, Reitz B, and **Morris RE**: The alpha-Gal polymer GAS914 depletes anti-alpha-Gal antibodies and prevents hyperacute rejection of hDAF-transgenic pig cardiac and renal xenografts in cynomolgus monkey. *Xenotransplantation*, 8: supplement 1, 77. August 2001.
123. Lam T, Hausen B, Jacobsen W, Baluom M, Pelletier M, Dambrin C, Duthaler R, Katopodis A, Harrison R and **Morris RE**: The effect of soluble complement receptor type 1 on survival of HDAF-transgenic pig cardiac and renal grafts in cynomolgus monkeys. *Xenotransplantation*, 8: supplement 1, 81. August 2001.
124. Lam T, Boeke K, and **Morri RE**: Anti-pig hemolytic antibody levels in cynomolgus monkeys from Indonesia, Mauritius, and the Philippines, and in baboons from Kenya. *Xenotransplantation*, 8: supplement 1, 85. August 2001.
125. Lam T, Hausen B, Hook L, Boeke K, Dambrin C, Higgins J, Berry G, Davies H, Cozzi E and **Morris RE**: High levels of anti-pig hemolytic antibodies are associated with hyperacute rejection of hDAF-transgenic pig cardiac and renal xenografts in cynomolgus monkeys. *Xenotransplantation*, 8: supplement 1, 86. August 2001.
126. Lam T, Lau M, Higgins J, Berry G, Duthaler R, Katopodis A, Robbins R, Reitz B, Hausen B and **Morris RE**: Anti alpha-Gal antibody responses in cynomolgus monkey

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

- recipients of hDAF-transgenic pig cardiac and renal xenografts. *Xenotransplantation*, 8: supplement 1, 96. August 2001.
127. Lam T, Lau M, Boeke K, Hausen B, Hook L, Duthaler R, Katopodis A and **Morris RE**: Natural xenoreactive anti-pig hemolytic antibodies with non-alpha-Gal specificity in cynomolgus monkeys from Mauritius. *Xenotransplantation*, 8: supplement 1, 96. August 2001.
128. Berry G, Lam T and **Morris RE**: Histopathological findings in cardiac xenografts from hDAF-transgenic pigs into cynomolgus monkeys. *Xenotransplantation*, 8: supplement 1, 106. August 2001.
129. Kambham N, Higgins J, Hausen B, Lam T and **Morris RE**: Steroid-responsive rejection episodes in cynomolgous monkey recipients of hDAF-transgenic pig renal xenografts. *Xenotransplantation*, 8: supplement 1, 107. August 2001.
130. Higgins J, Lam T, Chavez G, Schuurman H, Hausen B and **Morris RE**: Cellular infiltrates in renal xenografts from hDAF-transgenic pigs transplanted into cynomolgus monkeys. *Xenotransplantation*, 8: supplement 1, 108. August 2001.
131. Lam T, Bode M, Gizzi J, King H, Hook L, Hausen B and **Morris RE**: Serum electrolytes and total protein in cynomolgus monkey recipients of hDAF-transgenic pig renal xenografts. *Xenotransplantation*, 8: supplement 1, 131. August 2001.
132. Dambrin C, Birsan T, Klupp J, Hook L, Lam T, Christians U and **Morris RE**: New mechanisms of immunosuppression of sirolimus in vivo: Differential suppression of multiple immune functions of T and B cells and monocytes in non-human primates. *The American Journal of Transplantation*, 1: supplement 1, 167. May 2001.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

133. Hausen B, Lam T, Hook L, Boeke K, Christians U, Jacobsen W, Higgins J, Cozzi E, Davies H, Duthaler R, Harrison R, Katopodis A and **Morris RE**: The combined effects of pharmacologic neutralization of anti-Alpha-Gal antibodies and complement inhibition on survival of hDAF Transgenic pig renal grafts in cynomolgus monkeys. *The American Journal of Transplantation*, 1: supplement 1, 152. May 2001.
134. Dambrin C, Klupp J, Birsan T, Luna J, Suzuki T, Lam T, Staehr P, Hausen B, Hook L, Christians U, Fitzgerald P, Berry G and **Morris RE**: Sirolimus (Rapamycin) monotherapy prevents graft vascular disease in non-human primates. *The American Journal of Transplantation*, 1: supplement 1, 227. May 2001.
135. Lam T, Hausen B, Hook L, Boeke K, Dambrin C, Higgins J, Berry G, Davies H, Cozzi E and **Morris RE**: High levels of natural anti-pig hemolytic antibodies are associated with hyperacute rejection of hDAF transgenic pig to cynomolgus monkey cardiac renal xenografts. *The American Journal of Transplantation*, 1: supplement 1, 458. May 2001.
136. Klupp J, Van Gelder T, Dambrin C, Boeke K, Regieli J, Billingham M and **Morris RE**: Novel pharmacodynamic assays of lymphocyte function and proliferation in peripheral blood are affected by MMF dose schedule and correlate with histological severity of rejection in rat heart transplant recipients. *The American Journal of Transplantation*, 1: supplement 1, 222. May 2001.
137. Klupp J, Dambrin C, Jacobson W, Christians U and **Morris RE**: A novel retinoic acid receptor-alpha selective agonist, ER-38925, successfully prevented acute and chronic rejection of mouse cardiac allografts. *The American Journal of Transplantation*, 1: supplement 1, 223. May 2001.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

138. Klupp J, Dambrin C, Jacobson W, Christians U and **Morris RE**: Pharmacodynamic assessment of immunosuppressive activity of steroids-results from a human phase I pilot study. *The American Journal of Transplantation*, 1: supplement 1, 223. May 2001.
139. Birsan T, Dambrin C, Klupp J, Patz J D, Shorthouse R and **Morris RE**: Ex vivo evaluation of the immunosuppressive effect of the leflunomide derivative FK 778 on whole blood lymphocytes of non-human primates. *The American Journal of Transplantation*, 1: supplement 1, 439. May 2001.
140. Birsan T, Dambrin C, Villanueva JC, Yatscoff RW and **Morris RE**: Ex vivo evaluation of the immunosuppressive effect of the novel calcineurin inhibitor ISATX 247 on whole blood lymphocytes of non-primates. *The American Journal of Transplantation*, 1: supplement 1, 439. May 2001.
141. Birsan T, Dambrin C, Hook L, Villanueva JC, Marsh KC, Kjuric SW, Mollison KW and **Morris RE**: In vivo evaluation of the novel immunosuppressant A-285222 in non-human primates. *The American Journal of Transplantation*, 1: supplement 1, 438. May 2001.
142. Birsan T, Dambrin C and **Morris RE**: In vivo pharmacokinetic/pharmacodynamic evaluation of the malononitrilamide FK 778 in non-human primates. Abstract book, 2nd International Congress of Immunosuppression, 174, 2001.
143. Birsan T, Dambrin C, Klupp J and **Morris RE**: Ex vivo evaluation of the immunosuppressive effects of the malononitrilamide FK 778 on whole blood

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

- lymphocytes of non-human primates. Abstract book, 2nd International Congress of Immunosuppression, 174, 2001.
144. Birsan T, Dambrin C, Marsh KC, Jacobsen W and **Morris RE**: Invivo evaluation of the novel immunosuppresant A-285222 in non-human primates. Abstract book, 2nd International Congress of Immunosuppression, 174, 2001.
145. Birsan T, Dambrin C, Yatscoff RW and **Morris RE**: Ex vivo evaluation of the immunosuppressive effects of ISA_{TX} 247 on whole blood lymphocytes of non-human primates. Abstract book, 2nd International Congress of Immunosuppression, 174, 2001.
146. Dambrin C, Birsan T, Klupp J, Hook L, Lam T, Christians U and **Morris RE**: New mechanisms of immunosuppression of sirolimus in vivo: differential suppression of multiple immune functions of T and B cells and monocytes in non-human primates. Abstract book, 2nd International Congress of Immunosuppression, 176, 2001.
147. Lam T, Hausen B, Duthaler R, Katopodis A, Harrison R and **Morris RE**: The effect of soluble complement receptor type 1 on survival of hDAF-transgenic pig cardiac and renal xenografts in cynomolgus monkeys. Abstract book, 2nd International Congress of Immunosuppression, 182, 2001.
148. Lam T, Hausen B, Squires E and **Morris RE**: Cyclophosphamide induced anemia in cynomolgus monkey recipients of hDAF-Transgenic pig cardiac and renal xenografts. Abstract book, 2nd International Congress of Immunosuppression, 182, 2001.
149. Lam T, Hausen B, Duthaler R, Katopodis A and **Morris RE**: The alpha-Gal polymer GAS 914 prevents hyperacute rejection of hDAF-Transgenic pig xenografts in

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

- cynomolgus monkeys. Abstract book, 2nd International Congress of Immunosuppression, 182, 2001.
144. Stalder M, Birsan T, Hausen B and **Morris RE**: immunosuppressive effect of surgery after nephrectomy in non-human primates. Abstract book, 2nd International Congress of Immunosuppression, 189, 2001.
145. Stalder M, Birsan T, Hubble R, Paniagua R and **Morris RE**: Pharmacokinetic/pharmacodynamic (PD) evaluation of the novel calcineurin inhibitor ISA_{TX} in non-human primates. Abstract book, 2nd International Congress of Immunosuppression, 174, 2001.
146. Kyles AE, Gregory CR, Griffey SM, Pierce J, Bernsteen L and **Morris RE**: Combined immunosuppression with FK778 and cyclosporine prolongs renal allograft survival in mismatched mongrel dogs. The American Transplant Congress Meeting, April 26-May 1, 2002, Washington, D.C. American Journal of Transplantation 2 suppl. 3: 384.
147. Kyles AE, Gregory CR, Griffey SM, Bernsteen L, Pierce J, Lilja H, and **Morris RE**: immunosuppression with a combination of FK778 and cyclosporine prolongs renal allograft survival in mismatched mongrel dogs. Veterinary Surgery 2002: 31:487
148. Kyles AE, Gregory CR, Griffey SM and **Morris RE**: Leflunomide analog, HMR715, plus cyclosporine reduces renal allograft rejection in mismatched dogs. Proceedings of the XVIII International Congress of the Transplantation Society 2002, Rome, p. 277.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

149. Birsan T, Dambrin C, Klupp J, Stalder M, Fitzsimmons WE, **Morris RE**, Effects of the malononitrilamide FK778 on immune functions in vitro in whole blood from non-human primates and healthy human volunteers, *Transplant Immunology* 11 (2003) 163-167
150. Klupp J, Dambrin C, Hibi K, Luna J, Suzuki T, Hausen B, Birsan T, van Gelder T, Fitzgerald PJ, Berry G, **Morris RE**, Treatment by Mycophenolate Mofetil of Advanced Graft Vascular Disease in Non-Human Primate Recipients of Orthotopic Aortic Allografts, *American Journal of Transplantation* 2003; 3: 817 – 829
151. Birsan T, Dambrin C, Klupp J, Stalder M, Larson MJ, Fitzsimmons WE, **Morris RE**, In vivo pharmacokinetic and pharmacodynamic evaluation of the malononitrilamide FK778 in non-human primates, *Transplant International* (2003) 16: 354-360
152. Borie DC, Larson M, Changelian PS, Ball D, Higgins JP, Si M-S, Holm B, Flores M, Woodworth T, Kudlacz E, Brissette W, Gaweco A, Beals C, Littman B, Elliott E, Reitz BA, **Morris RE**: Targeted inhibitions of JAK3 with CP-690,550 significantly prolongs allograft survival in a nonhuman primate model of renal transplantation. *Am. J. Transplant.* 2003, 3[S-5], #4, p. 152.
153. Paniagua R, Holm B, Aalami O, Si M-S, Changelian P, Ball D, Kudlacz, Brissette W, Woodworth T, Elliot E, Larson M, **Morris RE**, Reitz B, Borie DC. The JAK3 inhibitor CP-690,550 significantly inhibits immune responses in vivo as revealed by pharmacodynamic monitoring of naïve and transplanted cynomolgus monkeys. *Am. J. Transplant.* 2003, 3[S-5], #412, p. 257.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

154. Si M-S, Lau M, Meyer T, **Morris RE**, Reitz BA, Borie DC: Effects of the kinase inhibitor CGP41251 on human T-Lymphocyte activation and function. *Am. J. Transplant.* 2003; 3[S-5], #413, p. 257.
155. Si S-M, Larson M, Changelian P, Ball D, Lau M, Flores M, Paniagua R, Holm B, **Morris RE**, Reitz B, Borie DC: Maintained renal function and homeostatic indices following renal transplantation in nonhuman primates immunosuppressed with the new JAK3 inhibitor CP-690,550. *Am. J. Transplant.* 2003; 3[S-5], #414, p. 257
156. Zhang S, Si M-S, Chagelian P, Lau M, Flores M, Paniagua R, **Morris RE**, Reitz B, Borie DC: Blockade of cytotoxic lymphocyte gene expression in cynomolgus monkeys treated with the JAK3 inhibitor CP-690,550. *Am. J. Transplant.* 2003; 3[S-5], #959, p. 397.
157. Zhang S, Si M-S, Lau M, Paniagua R, Holm B, **Morris RE**, Reitz B, Borie DC: Gene expression analysis in renal allografts: A comparative study in native and terminally rejected grafts in cynomolgus monkeys. *Am. J. Transplant.* 2003; 3[S-5], #962, p. 397.
158. Si MS, Lau M, Meyer T, **Morris RE**, Reitz BA, Borie DC: Effects of the kinase inhibitor CGP41251 on human T-Lymphocyte activation and function. *Am. J. Transplant.* 2003; 3[S-5], 257
159. The First-In-Class Oral Protein Kinase C (PKC) Inhibitor, NVP-AEB071, Prolongs Renal Allograft Survival in Non-Human Primates (NHP) and Suppresses Lymphocyte Proliferation at Safe Exposures in Human Proof-of-Concept Studies. Wagner J, Evenou J-P, Zenke G, Brinkmann V, Pally C, Bigaud M, Burkhart C, Cottens S, Jung T, Rordorf C, **Morris RE**: *American J. Transplant.* 6, Suppl 2: 86, Abstract 57, 2006.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

160. NVP-AEB071 (AEB), A Novel Oral Inhibitor of Early T-Cell Activation, Prolongs the Survival of Non-Human Primate (NHP) Kidney Allografts When Used As Monotherapy or At Non-Effective Doses Combined With a Non-Effective Dose of Cyclosporine (CsA). Bigaud M, Wieczorek G, Reisen S, Menninger K, Barbet I, Jean, C, Beerli, C, Audet M, Blancher A, Heusser C, Wagner J, **Morris RE**: American J. Transplant. 6, Suppl 2: 250, Abstract 546, 2006.
161. NVP-AEB071 (AEB), The Novel Oral Inhibitor of Early T-Cell Activation, Prolongs the Survival of Non-Human Primates (NHP) Kidney Allografts Survival When Combined with Everolimus (RAD), ERL080 (ERL) or FTY720 (FTY) Without Calcineurin Inhibitor. Bigaud M, Wieczorek G, Preussing E, Reisen S, Cordoba F, Audet M, Blancher A, Heusser C, Bruns C, Wagner J, **Morris RE**: American J. Transplant. 6, Suppl 2: 251, Abstract 550, 2006.
162. NVP-AEB071 (AEB), A Novel Oral Inhibitor of Early T-Cell Activation, Prolongs Rat Cardiac Allograft Survival When Used Alone and In Combination With Cyclosporine, Everolimus, or FTY720. Bruns C, Pally C, Beerli C, Wieczorek G, Wagner J, **Morris RE**: American J. Transplant. 6, Suppl 2: 316, Abstract 741, 2006.
163. Pharmacodynamics (PD) of T-Cell Inhibition by the New Protein Kinase C (PKC) Inhibitor, NVP-AEB071 (AEB) in Non-Human Primates (NHP). Bigaud M, Burkhart C, Raulf F, Vedrine C, Maurer C, Allard C, Preussing E, Cordoba F, Heusser C, **Morris RE**: American J. Transplant. 6, Suppl 2: 697, Abstract 1896, 2006.
164. First Escalating Single Dose Human Volunteer Study of the Novel Immunosuppressant (IS) NVP-AEB071 (AEB): Relationships among Dose Levels, PK and PD of Immune Functions. Burkhart C, Welzenbach K, Raulf F, Vitaliti A, Grenet O, Schmidli H, Belleli R, Marbach P, Wagner J, **Morris RE**, Rordorf C: American J.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

Transplant. 6, Suppl 2: 698, Abstract 1897, 2006.

165. Pharmacokinetics (PK) of the Novel Oral Protein Kinase C (PKC) Inhibitor NVP-AEB071 (AEB) in Rats and Non-Human Primates (NHP): Study of Immunosuppressive (IS) Efficacy and Distribution to Lymphatic Organs. Weckbecker G, Jean C, Pally C, Wagner J, **Morris RE**, Bruns C: American J. Transplant. 6, Suppl 2: 768, Abstract 2114, 2006.
166. Enzymatic & Cellular Characterization of NVP-AEB071 (AEB), A Novel & Selective Protein Kinase C (PKC) Inhibitor That Blocks Early T-Cell Activation, and Its Use to Define the Role of PKC in T Cells. Evenou J-P, Brinkmann V, Towbin H, Welzenbach K, Cottens S, Wagner J, **Morris RE**, Zenke G: American J. Transplant. 6, Suppl 2: 1026, Abstract 2954, 2006.
167. Selective Protein Kinase C Inhibitor Prevents Organ Allograft Rejection. Wagner J, Zenke G, Baier G, Bigaud M, Evenou J-P, Brinkmann V, Pally C, Wieczorek G, Weckbecker G, Beerli C, Bruns C, Heusser C, Burkhardt C, Welzenbach K, Kovarik J, Gruber T, Lutz-Nicoladoni C, Thuille N, Albert R, Cooke N, Sedrani R, van Eis M, Vangrevelinghe E, von Matt P, Marbach P, Dumortier T, Geiser M, Strauss A, Rummel G, Stark W, **Morris RE**, Rordorf C, Cottens S: In preparation.
168. Efficacy of NVP-AEB071, a Novel Oral Inhibitor of Early T-Cell Activation in GvH and Transplantation Models. Weckbecker G, Pally C, Beerli C, Burkhardt C, Wieczorek G, Metzler B, **Morris RE**, Wagner J, Bruns C: 4th International Leukocyte Signal Transduction Workshop: Clinical Implications of Signaling Pathways. Aegean Conferences, Rhodos/Greece, 2007

Burkhardt C, Welzenbach K, Raulf F, Vitaliti A, Grenet O, Schmidli H, Belleli R, Marbach P, Wagner J, Rordorf C, Slade A, **Morris RE**. NVP-AEB071 (AEB071) Suppression of immune

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

cell functions: Single dose Exposure-Response in humans. 2008. Intl conference on new trends in immunosuppression and immunotherapy.

PUBLICATIONS

Randall Ellis Morris, M.D., F.R.C.P. Fellow of Royal College of Physicians (Glasgow)

MISCELLANEOUS PUBLICATIONS

1. Brazelton TR, Doyle RL, Poirer C, Wong RL, Newmark RD, Lin T, Reitz BA, Theodore J, **Morris RE**, and the Stanford Lung Database Group, the International Lung Transplant Study Group and Novartis Pharmaceuticals. The Novartis Lung Transplant Database: White Paper. February 1998.